U.S. Stem Cell (USRM) 10-K 14 Apr 23 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Apr. 14, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	U.S. STEM CELL, INC.
Trading Symbol	USRM
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		641,507,317
Entity Public Float			$ 2,376,858
Amendment Flag	false
Entity Central Index Key	0001388319
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	FL
Entity File Number	001-33718
Entity Tax Identification Number	65-0945967
Entity Address, Address Line One	1560 Sawgrass Corporate Pkwy
Entity Address, Address Line Two	4th Floor
Entity Address, City or Town	Sunrise
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33323
City Area Code	954
Local Phone Number	835-1500
Title of 12(b) Security	Common Stock, $0.001 par value
Security Exchange Name	NONE
Entity Interactive Data Current	Yes
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	587
Auditor Name	RBSM LLP
Auditor Location	New York, NY

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,133	$ 39,393
Accounts receivable, net of allowance of $75,000	4,332	1,213
Inventories	980	393
Prepaid expenses and other current assets	57,594	10,000
Total current assets	68,039	50,999
Total assets	68,039	50,999
Current liabilities:
Accounts payable	1,624,583	1,373,413
Accrued expenses	2,582,559	1,951,390
Advances - related parties	1,137,642	951,432
Contract liabilities, current portion	3,000	3,000
Deposits	465,286	465,286
Notes payable - related parties	3,894,200	3,144,200
Notes payable, current portion, net of debt discount of $10,515 and $10,052, respectively	2,582,083	2,557,881
Promissory note payable	1,397,762	1,397,762
Convertible notes payable, net of debt discount of $37,224 and $0, respectively	390,776	194,411
Total current liabilities	14,077,891	12,038,775
Long-term liabilities:
Contract liabilities	53,500	56,500
Notes payable, net of debt discount of $11,059 and $21,575, respectively	682,044	722,060
Total long-term liabilities	735,544	778,560
Total liabilities	14,813,435	12,817,335
Commitments and contingencies (See Note 11)
Stockholders' deficit:
Preferred stock, par value $0.001; 20,000,000 shares authorized, -0- issued and outstanding	0	0
Common stock, par value $0.001; 2,000,000,000 shares authorized, 634,402,623 and 503,525,051 shares issued and outstanding, respectively	634,403	503,525
Additional paid-in capital	127,137,483	126,532,063
Accumulated deficit	(142,517,282)	(139,801,924)
Total stockholders' deficit	(14,745,396)	(12,766,336)
Total liabilities and stockholders' deficit	$ 68,039	$ 50,999

BALANCE SHEETS (Parentheticals)

BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Accounts receivable, allowance (in Dollars)	$ 75,000	$ 75,000
Debt discount (in Dollars)	$ 11,059	$ 21,575
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	634,402,623	503,525,051
Common stock, shares outstanding	634,402,623	503,525,051
Notes Payable, Other Payables [Member]
Debt discount (in Dollars)	$ 10,515	$ 10,052
Convertible Debt [Member]
Debt discount (in Dollars)	$ 37,224	$ 0

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Revenue	$ 82,049	$ 200,749
Cost of revenues	23,767	52,030
Gross profit	58,282	148,719
Operating expenses:
Selling, general and administrative	1,778,766	2,284,577
Total operating expenses	1,778,766	2,284,577
Loss from operations	(1,720,484)	(2,135,858)
Other income (expense):
Gain (loss) on settlement of accounts payable and accrued interest, net	12	(151,410)
Interest expense	(689,977)	(1,000,148)
Gain (loss) on debt extinguishment	(447,494)	0
Total other income (expense)	(1,137,459)	(1,151,558)
Net loss before income taxes	(2,857,943)	(3,287,416)
Income taxes (benefit)	0	0
NET LOSS	$ (2,857,943)	$ (3,287,416)
Net loss per common share, basic and diluted (in Dollars per share)	$ 0	$ (0.01)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	591,558,288	460,794,491
Product [Member]
Revenue:
Revenue	$ 66,540	$ 180,894
Service [Member]
Revenue:
Revenue	$ 15,509	$ 19,855

STATEMENT OF STOCKHOLDERS' DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2020	$ 0	$ 435,561	$ 124,499,655	$ (136,514,508)	$ (11,579,292)
Balance (in Shares) at Dec. 31, 2020	0	435,560,794
Modified retrospective adoption of ASU 2020-06 | Accounting Standards Update 2020-06 [Member]			(384,174)	142,585	(241,589)
Modified retrospective adoption of ASU 2020-06					0
Common stock issued in settlement		$ 6,642	225,100		231,742
Common stock issued in settlement (in Shares)		6,642,197
Common stock issued in lieu of interest		$ 931	18,869		19,800
Common stock issued in lieu of interest (in Shares)		930,916
Common stock issued for services		$ 4,000	124,000		$ 128,000
Common stock issued for services (in Shares)		4,000,000			4,000,000
Common shares issued as equity kicker for convertible notes payable					$ 0
Beneficial conversion feature recognized on convertible notes			641,688		641,688
Common stock issued for cash		$ 27,500	247,500		$ 275,000
Common stock issued for cash (in Shares)		27,500,000			27,500,000
Common stock issued upon conversion of convertible notes		$ 28,891	346,695		$ 375,586
Common stock issued upon conversion of convertible notes (in Shares)		28,891,144
Stock based compensation			428,556		428,556
Net loss				(3,287,416)	(3,287,416)
Balance (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021		$ 503,525	126,147,889	(139,659,339)	(13,007,925)
Balance at Dec. 31, 2021		$ 503,525	126,532,063	(139,801,924)	(12,766,336)
Balance (in Shares) (Accounting Standards Update 2020-06 [Member]) at Dec. 31, 2021		503,525,051
Balance (in Shares) at Dec. 31, 2021		503,525,051
Modified retrospective adoption of ASU 2020-06					384,174
Common stock issued in settlement		$ 6,146	42,671		48,817
Common stock issued in settlement (in Shares)		6,145,193
Common stock issued in lieu of interest		$ 2,499	17,012		19,511
Common stock issued in lieu of interest (in Shares)		2,499,045
Common stock issued for services		$ 45,000	252,000		$ 297,000
Common stock issued for services (in Shares)		45,000,000			45,000,000
Common shares and warrants issued to noteholders per addendums to convertible notes payable		$ 53,400	438,207		$ 491,607
Common shares and warrants issued to noteholders per addendums to convertible notes payable (in Shares)		53,400,000
Common shares issued as equity kicker for convertible notes payable		$ 6,750	11,813		18,563
Common shares issued as equity kicker for convertible notes payable (in Shares)		6,750,000
Common stock issued for cash		$ 13,958	71,042		$ 85,000
Common stock issued for cash (in Shares)		13,958,334			13,958,334
Common stock issued upon conversion of convertible notes		$ 3,125	21,875		$ 25,000
Common stock issued upon conversion of convertible notes (in Shares)		3,125,000
Stock based compensation			134,974		134,974
Net loss				(2,857,943)	(2,857,943)
Balance at Dec. 31, 2022		$ 634,403	$ 127,137,483	$ (142,517,282)	$ (14,745,396)
Balance (in Shares) at Dec. 31, 2022		634,402,623

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,857,943)	$ (3,287,416)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt (recoveries)	616	93,241
Interest and amortization of debt discount	685,326	977,386
Loss (gain) on settlement of accounts payable and accrued interest	(12)	151,410
Loss on debt extinguishment	447,494	0
Related party notes payable issued for services rendered	750,000	422,722
Share-based compensation	384,380	556,556
Changes in operating assets and liabilities:
Accounts receivable	(3,735)	(40,290)
Inventories	(587)	5,025
Accounts payable	274,268	73,195
Accrued expenses	18,341	(6,768)
Contract liabilities	(3,000)	(3,000)
Net cash used in operating activities	(304,852)	(1,057,939)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common shares	85,000	275,000
Proceeds from related party advances	186,210	90,000
Repayments of notes payable	(17,618)	(52,238)
Proceeds from convertible note payable	27,000	766,000
Repayments of convertible note payable	(10,000)	0
Net cash provided by financing activities	270,592	1,078,762
Net increase (decrease) in cash and cash equivalents	(34,260)	20,823
Cash and cash equivalents, beginning of period	39,393	18,570
Cash and cash equivalents, end of period	5,133	39,393
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Interest paid	6,113	22,762
Income taxes paid	0	0
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Modified retrospective adoption of ASU 2020-06	384,174	0
Common shares issued	47,594	0
Common shares issued upon conversion of convertible notes and accrued interest	25,000	375,586
Common shares issued as equity kicker for convertible notes payable	18,563	0
Common shares issued in lieu of interest	19,511	19,800
Monthly payments on notes payable made on behalf of the Company	8,250	0
Beneficial conversion feature recognized on convertible note	0	641,688
Accounts Payable and Accrued Liabilities [Member]
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common shares issued	$ 48,817	$ 231,742

NATURE OF OPERATIONS

NATURE OF OPERATIONS	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Nature of Operations [Text Block]	NOTE 1 NATURE OF OPERATIONS U.S. Stem Cell, Inc. was incorporated under the laws of the State of Florida in August 1999. The Company is in the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The business includes the development of proprietary cell therapy products as well as revenue generating physician and patient-based regenerative medicine/cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of cell therapy clinics. To date, the Company has not generated significant revenues in that they remain less than their total operating expenses, has incurred expenses, and has sustained losses. Consequently, its operations are subject to all the risks inherent in the establishment of a research and development business enterprise.

GOING CONCERN AND MANAGEMENT'S

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 GOING CONCERN AND MANAGEMENT S LIQUIDITY PLANS The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, as of December 31, 2022, the Company had cash on hand of $5,133 and a working capital deficit (current liabilities in excess of current assets) of $14,009,852. During the year ended December 31, 2022, the net loss was $2,857,943 and net cash used in operating activities was $304,852. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for one year from the issuance of the financial statements. The Company’s primary source of operating funds has been from revenue generated from sales with additional cash proceeds from the sale of common stock and the issuances of promissory notes and other debt. The Company has experienced net losses from operations since inception, but it expects these conditions to improve in the future as it develops its business model. The Company had a stockholders’ deficit at December 31, 2022 and requires additional financing to fund future operations. The Company’s existence is dependent upon management’s ability to develop profitable operations and to obtain additional funding sources. There can be no assurance that the Company’s financing efforts will result in profitable operations or the resolution of the Company’s liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	NOTE 3 SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include stock-based compensation, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. Fair Value Measurements Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable, accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts. Credit is extended to customers based on an evaluation of their financial condition, industry reputation, and other judgmental factors considered by the Company’s management. The Company generally does not require collateral or other security interest to support accounts receivable. Based on trends and specific factors, the customer’s credit terms may be modified, including required payment upon delivery. The Company performs regular on-going credit evaluations of its customers as deemed relevant. As events, trends, and circumstance warrant, the Company’s management estimates the amounts that are more likely than not to be uncollectible. These amounts are recognized as bad debt expense and are reflected within selling, general, administrative and other expenses on the Company’s accompanying statements of operations. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, the allowance for doubtful accounts was $75,000. Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs. Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10”) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 49.9% member interest ownership of U.S. Stem Cell Clinic, LLC and its 49% member interest ownership of U.S. Stem Cell Clinic of the Villages utilizing the equity method of accounting (See Note 4). Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606 “Revenue from Contracts with Customers” (“ASC 606”). ASC 606 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from in-person trainings are recognized when the training occurs and revenues from on demand online trainings are recognized when the customer purchases the rights to the training course. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking are accounted for as multiple performance obligations as described in ASC 606 and addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on stand-alone pricing. The multiple performance obligations include stem cell banking, dose retrieval and yearly storage fees. Revenues for stem cell banking and dose retrieval is recognized at the point of service and revenues for the yearly storage fees is recognized over the term of the banking contract, which is typically one year with annual renewals. At December 31, 2022 and 2021, the Company had contract liabilities of $56,500 and $59,500, respectively, all of which relates to the Intellectual Property Licensing Agreement. Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company did not incur any research and development expenses during the periods presented. Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For stock-based awards to employees, non-employees and directors, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Net Loss per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “if converted” method. The computation of basic and diluted income (loss) per share as excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: December 31, 2022 2021 Options 110,641,384 110,643,884 Warrants 13,583,127 1,103,127 Convertible notes 36,455,827 17,876,880 Total potentially dilutive shares 160,680,338 129,623,891 Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on accounting for convertible debt instruments by removing the separation models for: (1) convertible debt with a cash conversion feature; and (2) convertible instruments with a beneficial conversion feature. As a result, the Company will not separately present in equity an embedded conversion feature in such debt. Instead, we will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. We expect the elimination of these models will reduce reported interest expense and increase reported net income for the Company’s convertible instruments falling under the scope of those models before the adoption of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The Company adopted ASU 2020-06 in the first quarter of 2022 utilizing the modified retrospective method. As a result, the Company adjusted its beginning balance sheet with a decrease in additional paid-in capital of $384,174, offset by a decrease in debt discount on convertible debt of $241,589 and an increase in accumulated deficit of $142,585. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”, which significantly changes how entities will measure credit losses for most financial assets, including accounts receivable. ASU No. 2016-13 will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. On November 15, 2019, the FASB delayed the effective date of Topic 326 for certain small public companies and other private companies until fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and not-for-profit entities. The Company does not expect the new guidance will have a material impact on its financial statements. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

INVESTMENTS

INVESTMENTS	12 Months Ended
	Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract]
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 4 INVESTMENTS During March 2021, we divested ourselves of our Member Interest in U.S. Stem Cell Clinic, LLC, while U.S. Stem Cell Clinic of the Villages, LLC is currently dormant. U.S. Stem Cell Clinic, LLC The investment in U.S. Stem Cell Clinic, LLC was comprised of a 49.9% (increased from 33.3% on January 29, 2019) member interest ownership and is accounted for using the equity method of accounting. The Company’s income (loss) earned by U.S. Stem Cell Clinic, LLC member interest was $0 for the year ended December 31, 2022 and 2021, (inception to date income of $599,721) and is included in other income (expense) in the accompanying statements of operations. In addition, during the year ended December 31, 2022 and 2021, the Company received distributions totaling $0 from U.S. Stem Cell Clinic, LLC (inception to date of $663,870). In March 2021, the Company divested its entire interest in U.S. Stem Cell Clinic, LLC (See Note 5, 6 and 11). The carrying value of the investment at December 31, 2022 and 2021 is $0. At December 31, 2022 and 2021, accounts receivable for sales of product and services to U.S. Stem Cell Clinic, LLC was $0 and $28,763, respectively. Revenues earned from sales to U.S. Stem Clinic, LLC for the year ended December 31, 2022 and 2021 were $0 and $2,531 (prior to divestiture), respectively. An affiliate of one of the Company’s officers is a minority investor in the U.S. Stem Cell Clinic, LLC. U.S. Stem Cell of the Villages LLC On January 30, 2018, Greg Knutson, a director of the Company (“Knutson”) and the Company agreed to open and operate a regenerative medicine/cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases in Florida. To that end, U.S. Stem Cell Clinic of The Villages LLC (the “Villages”) was formed January 30, 2018. Knutson provided the Company with the sum of Three Hundred Thousand Dollars ($300,000) (the “Investment”) to be utilized for the formation and initial operation of the Villages. Currently, Knutson holds a 51% member interest in the Villages and the Company holds a 49% member interest. The Company will provide operating assistance as well as management services, the latter to be compensated at fee of five percent (5%) of the Villages gross revenues. As of December 31, 2018, upon completion of U.S. Stem Cell of the Villages LLC, the Company received $189,909 from Greg Knutson, the holder of the 51% member interest. Accordingly, this was recognized as additional paid-in capital. Subsequently, the Company contributed $86,750 as its initial investment in the Villages. The Company’s 49% income (loss) earned by the Villages member interest was $0 for the three and nine months ended September 30, 2022 and 2021, (inception to date loss of $23,050) and is included in other income (expense) in the accompanying statements of operations. In addition, during the nine months ended September 30, 2022 and 2021, the Company received distributions totaling $0 from the Villages. The carrying value of the investment at September 30, 2022 and December 31, 2022 is $0. At December 31, 2022 and 2021, accounts receivable for sales of products and services to the Villages was $0. Revenues earned from sales to the Villages for the year ended December 31, 2022 and 2021 was $0. During the year ended December 31, 2022 and 2021, the Company received $0 in management fees from the Villages. As of the date of this filing, U.S. Stem Cell Clinic of the Villages, LLC is currently dormant.

ACCRUED EXPENSES

ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 ACCRUED EXPENSES Accrued expenses consisted of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank $ 756,437 $ 644,670 Accrued interest payable 1,746,990 1,227,588 Vendor accruals and other 79,132 79,132 Total Accrued expenses $ 2,582,559 $ 1,951,390 On February 10, 2021, as part of a settlement agreement, the Company transferred its entire member interest in U.S. Stem Cell, LLC to Dr. Kristen Comella as settlement for $100,000 of accrued interest owed to Dr. Comella, resulting in a gain on settlement of $100,000 (See Note 4, Note 6 and Note 11 “Litigation”).

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTE 6 NOTES PAYABLE Notes payable were comprised of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Seaside Bank note payable $ 980,000 $ 980,000 Dr. Comella note payable* 255,579 255,579 Dr. Comella note payable* 300,000 300,000 Dr. Comella note payable* 300,000 300,000 Dr. Comella note payable* 300,000 300,000 Hunton & Williams note payable 373,500 380,000 Weider note payable 403,622 413,239 Mallard note payable 223,000 232,750 EIDL note payable 150,000 150,000 Total notes payable 3,285,701 3,311,568 Less unamortized debt discount (21,574 ) (31,627 ) Total notes payable net of unamortized debt discount 3,264,127 3,279,941 Less current portion (2,582,083 ) (2,557,881 ) Long-term portion $ 682,044 $ 722,060 * Dr. Comella is a former member of the Board of Directors and resigned on December 1, 2019. This note was previously included in notes payable - related parties. Seaside Bank On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain stockholders of the Company. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2018 to extend the maturity date to May 18, 2020. The Company renewed the loan with Seaside National Bank and Trust during the first quarter of 2020 to extend the maturity date to May 18, 2022. On October 25, 2010, the Company entered into a Loan Agreement with Seaside National Bank and Trust for a $980,000 loan at 4.25% per annum interest that was used to refinance the Company’s loan with Bank of America. The obligation is guaranteed by certain stockholders of the Company. At renewal in 2018, the loan with Seaside National Bank and Trust was converted to a demand note bearing interest at prime + 0%. While the loan no longer has a fixed maturity date, it must be re-documented every four years, which was last done October 25, 2022. Dr. Comella, former Chief Science Officer On September 6, 2016, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due upon demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $255,579. On August 7, 2017, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. As of December 31, 2022 and 2021, the remaining carrying value of the note was $300,000. On May 7, 2018, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due six months from date of issuance. As of December 31, 2022 and 2021, the remaining carrying value of the note was $300,000. On July 1, 2019, the Company issued a $300,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due November 7, 2019. As of December 31, 2022 and 2021, the remaining carrying value of the note was $300,000. On February 10, 2021, as part of a settlement agreement, the Company transferred its entire member interest in U.S. Stem Cell, LLC to Dr. Kristen Comella as settlement for $100,000 of accrued interest owed to Dr. Comella, resulting in a gain on settlement of $100,000 (See Note 4, Note 5 and Note 11 “Litigation”). At December 31, 2022 and 2021, accrued interest on the notes was $224,203 and $166,424, respectively, and is included in accrued expenses on the accompanying balance sheet. Dr. Comella has not served as member of the Board of Directors since September 1, 2019. Hunton & Williams At December 31, 2016, the Company has two outstanding notes payable with interest at 8% per annum due at maturity. The two notes, $61,150 and $323,822, are payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar Biotech Group, LLC (or successor) Loan is paid off. On August 31, 2017, the Company and the noteholder entered into a Note Forbearance, Modification and Repayment Agreement (“Agreement”). The two notes, $61,150 and $323,822, were payable in one balloon payment upon the date of a written demand and upon certain triggering events occurring. The sum of unpaid principal and accumulated interest for both notes as of August 31, 2017 of $747,680 and an accounts payable of $40,596 result in an aggregate balance due of $788,276. The noteholder agreed to accept full payment of their obligation over a four (4) year period in 48 monthly installments on an adjusted debt obligation in aggregate of $624,000 (reducing the outstanding balance), with such payments staggered in amounts such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year. In addition, the noteholder agreed to suspend accrual interest on the notes commencing September 1, 2017. The Agreement remains in full force and effect provided the Company continues to make the monthly payments, there is no event of default as defined in the notes and an agreement to a subordination agreement by Northstar Biotech Group, LLC, which has been provided. In May 2019, the Company did not make the required scheduled payment. In September 2019, the noteholder agreed to waive their default rights under the agreement provided a minimum of $5,000 was paid by the end of 2019 and to reduce the required monthly payment to $500 per month commencing in January 2020. The Company satisfied the $5,000 payment requirement by the end of 2019 and commenced making the required $500 monthly payments in January 2020. The Company last made a $500 payment in March 2021 and thereby became delinquent until making three $1,500 payments during the fourth quarter of 2021 (a total of $6,000 in payments were made during 2021) thereby becoming current as of December 31, 2021. The Company imputed an interest rate of 5% and discounted the note accordingly. The imputed debt discount of $69,700 was amortized to interest expense using the effective interest method. In September 2019, the Company was in default and was negotiating a revised payment structure. Thus, the remaining unamortized debt discount was charged to interest expense at September 30, 2019. As of December 31, 2022 and 2021, the remaining carrying value of the note was $373,500 and $380,000, respectively. Weider The Company, as one of the parties entered into a Settlement Agreement and General Release (the “Agreement”) dated June 3, 2019 related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year 5.25% unsecured promissory note, dated June 15, 2019, in the principal amount of $500,000, payable in monthly increments of $5,000 per month, with a final balloon payment due on June 15, 2024. Accordingly, the Company recognized Pre-litigation expense of $500,000. As of December 31, 2022 and 2021, the remaining carrying value of the note was $403,622 and $413,239, respectively. At December 31, 2022 and 2021, accrued interest on the note was $17,014 and $1,808, respectively, and is included in accrued expenses on the accompanying balance sheet. The Company last made a $5,000 payment in March 2022 and thereby became delinquent on this note payable. Mallard The Company, as one of the parties entered into a Settlement Agreement and General Release (the “Agreement”) dated December 6, 2019 related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year non-interest bearing unsecured promissory note, dated December 6, 2019, in the principal amount of $250,000, payable in monthly increments of $750 per month, with a final balloon payment of $205,000 due on January 1, 2025. The Company imputed an interest rate of 5% and discounted the note accordingly. The imputed debt discount of $51,063 is being amortized to interest expense using the effective interest method. Accordingly, the Company recognized Pre-litigation expense of $198,937. During the year ended December 31, 2022, U.S. Stem Cell Clinic made 11 monthly payments of $750 (total of $8,250) on behalf of the Company. For the year ended December 31, 2022 and 2021, the Company amortized $10,052 and $9,610, respectively, of debt discount to interest expense. As of December 31, 2022 and 2021, the remaining carrying value of the note was $201,426 and $201,123, net of debt discount of $21,574 and $31,627, respectively. Economic Injury Disaster Loan (EIDL) On June 20, 2020, the Company executed the standard loan documents for an EIDL from the U.S. Small Business Administration in light of the impact of the COVID-19 pandemic on our business. Pursuant to that certain Loan Authorization and Agreement (the “SBA Loan Agreement”), the principal amount of the EIDL received was $150,000, with proceeds to be used for working capital purposes. Interest accrues at the rate of 3.75% per annum. Installment payments, including principal and interest, are due monthly beginning June 20, 2021 (twelve months from the date of the SBA Loan Agreement) in the amount of $731. On March 15, 2021, the initial payment date was extended 12 months to June 20, 2022. On March 15, 2022, the initial payment date was extended 6 months to December 20, 2022. The balance of principal and interest is payable thirty years from the date of the SBA Loan Agreement. As of December 31, 2022 and 2021, the remaining carrying value of the note was $150,000. At December 31, 2022 and 2021, accrued interest on the note was $13,509 and $8,615, respectively, and is included in accrued expenses on the accompanying balance sheet.

PROMISSORY NOTE PAYABLE

PROMISSORY NOTE PAYABLE	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Short-Term Debt [Text Block]	NOTE 7 PROMISSORY NOTE PAYABLE On June 1, 2015, the Company issued an amended and restated promissory note of $1,697,762 in settlement of the $1,500,000 outstanding subordinated debt, related accrued interest of $373,469 and accumulated and unpaid guarantor fees of $624,737. The note is unsecured and non-interest bearing and required four semi-annual payments of $75,000 beginning on December 31, 2015 with the remaining unpaid balance due June 1, 2020. On June 1, 2020, the Company defaulted on the promissory note. Upon default, the note became due in full and the Company began accruing interest at the default interest rate of 18%. The Company imputed an interest rate of 5% and discounted the promissory note accordingly. The imputed debt discount of $368,615 was amortized to interest expense using the effective interest method. As of December 31, 2022 and 2021, the remaining carrying value of the note was $1,397,762. At December 31, 2022 and 2021, accrued interest on the note was $650,017 and $398,420, respectively, and is included in accrued expenses on the accompanying balance sheet.

CONVERTIBLE NOTE PAYABLE

CONVERTIBLE NOTE PAYABLE	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt [Text Block]	NOTE 8 CONVERTIBLE NOTES PAYABLE The Company adopted ASU 2020-06 in the first quarter of 2022 utilizing the modified retrospective method. As a result, the Company eliminated an aggregate of $241,589 of debt discount stemming from beneficial conversion features on convertible debt. Accordingly, the Company will not separately present in equity an embedded conversion feature in such debt. On February 5, 2020, the Company issued an unsecured convertible promissory note in the principal amount of $35,000 that matured on February 5, 2021 and accrued interest at a rate of 5% per annum. The investor had the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price equal to a thirty percent (30%) discount of the average closing price of the Company’s common stock on the OTC Markets electronic exchange for the prior thirty (30) trading days prior to conversion, subject to adjustment. Upon the occurrence of an event of default, the investor may have accelerated the note pursuant to which the outstanding balance would become, at the noteholder’s election, immediately due and payable. As a result of the beneficial conversion feature of the note, debt discount of $15,000 was recognized with a corresponding increase in additional paid-in capital. The debt discount was amortized to interest expense using the effective interest method. As of February 5, 2021, the maturity date, the note was in default. On July 30, 2021, the investor converted the full value of the note into 3,804,348 shares of the Company’s common stock. The agreement contains a provision that in the event the conversion right is exercised, then the Holder waives all outstanding interest. Accordingly, all outstanding accrued interest at the time of conversion was reversed. The debt discount was amortized to interest expense using the effective interest method. For the year ended December 31, 2022 and 2021, the Company amortized $0 and $1,874, respectively, of debt discount to interest expense. As of December 31, 2022 and 2021, the remaining carrying value of the note was $0. At December 31, 2022 and 2021, accrued interest on the note was $0. On September 8, 2020, the Company issued an unsecured convertible promissory note in the principal amount of $10,000 that was due on demand and accrued interest at a rate of 5% per annum. The investor had the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price of $0.0467. Upon the occurrence of an event of default, the remaining principal and accrued interest become immediately due and payable, with interest accruing at 18% per annum on any unpaid amounts. On November 9, 2021, the investor converted the entire principal balance of $10,000 and accrued interest of $588 into 226,713 shares of the Company’s common stock. As the conversion was at a fixed conversion price, no gain or loss was recognized on conversion. As of December 31, 2022 and 2021, the remaining carrying value of the note was $0. As of December 31, 2022 and 2021, accrued interest on the note was $0. From February 17, 2021 through February 26, 2021, the Company issued unsecured convertible promissory notes in the aggregate principal amount of $619,000 that matured 12 months after the respective issuance date. The notes are non-interest bearing and the investor has the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price of $0.0266. The agreements contain a provision that in the event the conversion right is exercised, then the Holder waives all outstanding interest. Upon the occurrence of an event of default, the remaining principal and accrued interest become immediately due and payable. As a result of the beneficial conversion feature of the notes, an aggregate of $521,850 of debt discount was recognized with a corresponding increase in additional paid-in capital. The debt discount is being amortized to interest expense using the effective interest method. On March 23, 2021, one of the holders, a related party, converted a convertible note with a face value of $200,000, dated February 26, 2021, into 7,518,797 shares of the Company’s common stock. Upon conversion, the remaining unamortized debt discount was expensed immediately. In addition, all outstanding accrued interest at the time of conversion was reversed. As the conversion was at a fixed conversion price, no gain or loss was recognized on conversion (See Note 9 and 12). During the three months ended March 31, 2022, the Company entered into addendums with certain holders owning an aggregate of $294,000 of the convertible notes whereby: [1] for $214,000 of the convertible notes, the conversion price was changed from $0.0266 to $0.008, the maturity date was extended for two years and an aggregate of 53,400,000 common shares and five-year warrants to purchase 12,500,000 common shares at $0.008 per share were issued, having an aggregate fair value of $491,607; and [2] for $80,000 of the convertible notes, the interest rate was changed from 0% to 12% and the maturity date was extended for one year. As a result of the changes in the conversion price and the interest rate, the addendums resulted in an extinguishment of $294,000 of the old debt in exchange for new debt with the same face value, having aggregate debt discount of $44,113, and different terms. As part of one of the addendums, additional proceeds of $27,000 were received in exchange for a corresponding increase in the convertible note payable balance and 6,750,000 shares of common stock. Accordingly, a loss on debt extinguishment of $447,494 was recognized in the accompanying statements of operations. On March 11, 2022, one of the holders converted a convertible note with a face value of $25,000, dated February 26, 2021 (as amended on February 26, 2022), into 3,125,000 shares of the Company’s common stock. As the conversion was at a fixed conversion price, no gain or loss was recognized on conversion. During the year ended December 31, 2022 and 2021, $10,000 and $0, respectively, of convertible notes were repaid. As of December 31, 2022, $115,000 of convertible notes payable were in default. For the year ended December 31, 2022 and 2021, the Company amortized $25,451 and $141,586, respectively, of debt discount to interest expense. As of December 31, 2022 and 2021, the remaining carrying value of the notes was $373,775 and 419,000, net of debt discount of $37,224 and $0 respectively. On March 24, 2021, the Company issued an unsecured convertible promissory note in the principal amount of $110,000 that matured 12 months after the issuance date. The note was non-interest bearing and the investor had the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price of $0.0070. The agreement contains a provision that in the event the conversion right is exercised, then the Holder waives all outstanding interest. Upon the occurrence of an event of default, the remaining principal and accrued interest become immediately due and payable. As a result of the beneficial conversion feature of the note, $110,000 of debt discount was recognized with a corresponding increase in additional paid-in capital. The debt discount was being amortized to interest expense using the effective interest method. On November 9, 2021, the holder converted the full value of the note into 15,741,286 shares of the Company’s common stock. Upon conversion, the remaining unamortized debt discount was expensed immediately. In addition, all outstanding accrued interest at the time of conversion was reversed. As the conversion was at a fixed conversion price, no gain or loss was recognized on conversion (See Note 12). For the year ended December 31, 2021, the Company amortized $110,000 of debt discount to interest expense. As of December 31, 2022 and 2021, the remaining carrying value of the note was $0. On June 20, 2021, the Company issued an unsecured convertible promissory note in the principal amount of $20,000 that matured 12 months after the issuance date. The note was non-interest bearing and the investor had the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price of $0.0125. The agreement contains a provision that in the event the conversion right is exercised, then the Holder waives all outstanding interest. Upon the occurrence of an event of default, the remaining principal and accrued interest become immediately due and payable. As a result of the beneficial conversion feature of the note, $2,400 of debt discount was recognized with a corresponding increase in additional paid-in capital. The debt discount was being amortized to interest expense using the effective interest method. On November 9, 2021, the holder converted the full value of the note into 1,600,000 shares of the Company’s common stock. Upon conversion, the remaining unamortized debt discount was expensed immediately. In addition, all outstanding accrued interest at the time of conversion was reversed. As the conversion was at a fixed conversion price, no gain or loss was recognized on conversion (See Note 12). For the year ended December 31, 2021, the Company amortized $2,400 of debt discount to interest expense. As of December 31, 2022 and 2021, the remaining carrying value of the note was $0. On October 29, 2021, the Company issued an unsecured convertible promissory note in the principal amount of $17,000 that matures 12 months after the issuance date. The note is non-interest bearing and the investor has the right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price of $0.008. Upon the occurrence of an event of default, the remaining principal and accrued interest become immediately due and payable. As a result of the beneficial conversion feature of the note, $7,438 of debt discount was recognized with a corresponding increase in additional paid-in capital. The debt discount was being amortized to interest expense using the effective interest method. For the year ended December 31, 2021, the Company amortized $998 of debt discount to interest expense. As of December 31, 2022 and 2021, the remaining carrying value of the note was $17,000.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 9 RELATED PARTY TRANSACTIONS Advances – Related Parties As of December 31, 2022 and 2021, the Company’s officers and directors have provided advances that are unsecured, non-interest bearing and due on demand. During the year ended December 31, 2022 and 2021, the Company received aggregate proceeds from advances of $186,210 and $90,000, respectively. As of December 31, 2022 and 2021, the Company owed $1,137,642 and $951,432, respectively, for related party advances. Convertible Notes Payable – Related Parties On March 23, 2021, one of the holders, a related party, converted a convertible note with a face value of $200,000, dated February 26, 2021, into 7,518,797 shares of the Company’s common stock. (See Note 8). Notes Payable – Related Parties Northstar Biotechnology Group, LLC On February 29, 2012, a promissory note issued to BlueCrest Master Fund Limited (“BlueCrest”) was assigned to Northstar Biotechnology Group, LLC (“Northstar”), owned partly by certain directors and existing shareholders of the Company at the time, including Dr. William P. Murphy Jr., Dr. Samuel Ahn and Charles Hart. At the date of the assignment, the principal amount of the BlueCrest note was $544,267 (the “Note”). On March 30, 2012, the Company and Northstar agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May 1, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement. The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock. On September 21, 2012, the Company issued 5,000 common stock purchase warrants to Northstar that was treated as additional interest expense upon issuance. On October 1, 2012, the Company and Northstar entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights. In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Effective October 1, 2012, the interest rate was 12.85% per annum. The parties agreed, as of February 28, 2013, to reduce the interest rate to 7% per annum. In connection with the consideration paid, Northstar waived, from the effective date through the earlier of termination or expiration of the agreement, satisfaction of the obligations as described in the forbearance agreement. In 2012, 5,000,000 shares of Series A Convertible Preferred Stock were approved to be issued, which was subsequently increased to 20,000,000 shares of preferred stock as Series A Convertible Preferred Stock. In addition, the Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six-month anniversary of the effective date (October 1, 2012). In lieu of the initial two payments in preferred stock, the parties agreed to modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stockholders to 25 votes per share on matters to be voted on by the common stockholders and all prior and subsequent payments of interest will be in common stock. The Company is required to issue additional shares of its common stock (as amended), in lieu of cash, each six-month anniversary of the effective date for any accrued and unpaid interest. On September 30, 2013, the Company issued 8,772 shares of its common stock as payment of $100,000 towards principal. On December 24, 2013, the Company issued 3,916 shares of its common stock as payment of accrued interest through June 30, 2013 of $85,447. On April 2, 2014, the Company issued 275 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2014 per the forbearance agreement. On September 17, 2014, the limited waiver and forbearance agreement entered into on October 1, 2012 to provide that the perpetual license on products as described for resale, relicensing and commercialization outside the United States was amended as such on the condition that Northstar provide certain financing, which financing the Company, in its sole discretion, could decline and retain the license. On October 3, 2014, the Company issued 515 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2014 per the forbearance agreement. On April 3, 2015, the Company issued 1,363 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,635 due April 1, 2015 per the forbearance agreement. On October 2, 2015, the Company issued 4,156 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2015 per the forbearance agreement. On October 7, 2015, the Company issued 34,522 shares of its common stock in settlement of $100,000 principal payment towards the outstanding debt. On April 7, 2016, the Company issued 57,778 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due April 1, 2016 per the forbearance agreement. On October 6, 2016, the Company issued 848,490 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705 due October 1, 2016 per the forbearance agreement. On March 1, 2017, Northstar and the Company entered into a settlement agreement (“Settlement Agreement “) related to then pending litigation. Pursuant to the terms and conditions of the Settlement Agreement, Northstar converted its outstanding Series A Convertible preferred stock, into twenty million (20,000,000) shares of common stock according to the original conversion terms. In addition, and separate and apart from the conversion, Northstar received eleven million (11,000,000) shares of the Company’s common stock. Northstar will receive ten percent (10%) of all Company international sales (based on a gross sales basis). There was no effect of the 10% obligation as there were no international sales in 2017 or through 2019. Furthermore, a Northstar designee, Greg Knutson, was appointed as a member of the Board of Directors of the Company and two Company directors, Michael Tomas and Kristin Comella, each exercised their prior Northstar options to each receive a five percent (5%) member interest in Northstar. The parties agreed to a mutual release and Northstar agreed to terminate any UCC lien on the Company assets previously filed for the benefit of Northstar. On March 9, 2017 and April 1, 2017, the Company issued 30,000,000 and 1,000,000 shares of its common stock, respectively, as described above. In connection with the settlement, the Company recorded a loss on litigation settlement of $316,800. On April 1, 2017, the Company issued 286,315 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,703. On October 2, 2017, the Company issued 559,187 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $12,705. On October 19, 2018, the Company issued 164,523 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,195. On April 19, 2019, the Company issued 379,141 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,145. On October 1, 2019, the Company issued 1,692,353 shares of its common stock in lieu of payment in cash of accrued and unpaid interest of $9,195. On April 1, 2020, the Company issued 1,445,647 shares of its common stock, having a fair value of $11,565, in lieu of payment in cash of accrued and unpaid interest of $9,145, resulting in a loss on settlement of $2,420. On October 1, 2020, the Company issued 2,035,820 shares of its common stock, having a fair value of $10,179, in lieu of payment in cash of accrued and unpaid interest of $9,195, resulting in a loss on settlement of $984. On April 1, 2021, the Company issued 187,575 shares of its common stock, having a fair value of $10,879, in lieu of payment in cash of accrued and unpaid interest of $9,145, resulting in a loss on settlement of $1,734. On October 1, 2021, the Company issued 743,341 shares of its common stock, having a fair value of $8,921, in lieu of payment in cash of accrued and unpaid interest of $9,195, resulting in a gain on settlement of $274. On April 5, 2022, the Company issued 1,121,154 shares of its common stock, having a fair value of $9,866, in lieu of payment in cash of accrued and unpaid interest of $9,144, resulting in a loss on settlement of $722. On October 1, 2022, the Company issued 1,377,891 shares of its common stock, having a fair value of $9,645, in lieu of payment in cash of accrued and unpaid interest of $9,195, resulting in a loss on settlement of $450. As of December 31, 2022 and 2021, the remaining carrying value of the note was $262,000. At December 31, 2022 and 2021, accrued interest on the note was $8,751 and is included in accrued expenses on the accompanying balance sheet. Notes Payable - Mr. Tomas, President and Chief Executive Officer On August 7, 2017, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due one year from date of issuance. As of December 31, 2022 and 2021, the remaining carrying value of the note was $161,786. On May 7, 2018, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due six months from date of issuance. As of December 31, 2022 and 2021, the remaining carrying value of the note was $500,000. On July 1, 2019, the Company issued a $500,000 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due November 7, 2019. As of December 31, 2022 and 2021, the remaining carrying value of the note was $500,000. On December 31, 2019, the Company issued a $178,077 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $178,077. On March 31, 2020, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $187,500. On June 30, 2020, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $187,500. On July 1, 2020, the Company issued a $500,000 promissory note as payment of an annual bonus awarded. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $500,000. On September 30, 2020, the Company issued a $100,962 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $100,962. On December 31, 2020, the Company issued a $143,654 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $143,653. On March 31, 2021, the Company issued a $90,990 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $90,991. On June 30, 2021, the Company issued a $43,269 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $43,269. On September 30, 2021, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021, the remaining carrying value of the note was $187,500. On December 31, 2021, the Company issued a $100,962 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022 and 2021 the remaining carrying value of the note was $100,962. On March 31, 2022, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022, the remaining carrying value of the note was $187,500. On June 30, 2022, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022, the remaining carrying value of the note was $187,500. On September 30, 2022, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022, the remaining carrying value of the note was $187,500. On December 31, 2022, the Company issued a $187,500 promissory note in exchange for compensation earned. The promissory note bears interest of 5% per annum and is due on demand. As of December 31, 2022, the remaining carrying value of the note was $187,500. At December 31, 2022 and 2021, accrued interest on the notes was $770,585 and $612,323, respectively, and is included in accrued expenses on the accompanying balance sheet. December 31, 2022 2021 Northstar $ 262,000 $ 262,000 Note payable, Mr. Tomas 161,786 161,786 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 178,077 178,077 Note payable, Mr. Tomas 187,500 187,500 Note payable, Mr. Tomas 187,500 187,500 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 100,962 100,962 Note payable, Mr. Tomas 143,653 143,653 Note payable, Mr. Tomas 90,991 90,991 Note payable, Mr. Tomas 43,269 43,269 Note payable, Mr. Tomas 187,500 187,500 Note payable, Mr. Tomas 100,962 100,962 Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Total notes payable - related parties $ 3,894,200 $ 3,144,200

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 10 FAIR VALUE MEASUREMENT The Company adopted the provisions of ASC 825-10. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon Level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. As of December 31, 2022 and 2021, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures. As of December 31, 2022 and 2021, the Company did not have any derivative instruments that were designated as hedges.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 COMMITMENTS AND CONTINGENCIES Leases In October 2019, the Company relocated to a new location within the same city and entered into a month-to-month lease. During the year ended December 31, 2022 and 2021, lease expense was comprised of the following: For the Years Ended December 31, 2022 2021 Operating lease expense $ 6,541 $ 4,711 Total lease expense $ 6,541 $ 4,711 Royalty Agreement / Middle East On November 9, 2016, the Company entered into an Intellectual Property License Agreement whereby the Company granted High Rise Group Company the exclusive right to the Company’s intellectual property (as defined) for the licensed use and development in Kuwait and other GCC/Middle East countries for 25 years in exchange for a payment of $75,000 and a 5% royalty generated under the agreement. The licensing agreement is recorded as deferred revenue and amortized over the term of the agreement. The carrying balance as of December 31, 2022 and 2021 was $56,500 and $59,500, respectively. The intent is for U.S. Stem Cell Middle East to offer regenerative treatment options to patients, based on U.S. Stem Cell, Inc. products and technologies like MyoCell™. To date, the first clinic in Kuwait City has been completed but has not begun operations as High Rising Group has not yet been able to secure regulatory approvals to operate. Litigation On September 17, 2015, a product liability lawsuit was filed in Broward County, specifically Patsy Bade v. Bioheart, Inc. US Stem Cell Clinics LLC, Alejandro Perez, ARNP, and Shareen Greenbaum, M.D., and on November 30, 2015, a product liability lawsuit was filed in Broward County, specifically Elizabeth Noble v. Bioheart, Inc. US Stem Cell Clinics LLC, Alejandro Perez, ARNP, and Shareen Greenbaum, M.D. During the year ended December 31, 2016, both matters settled by the Company’s insurance policy with no additional cost to the Company, except for the obligation to pay the insurance company deductible of $100,000, of which $11,000 was paid in fiscal 2017. The remaining amount due under this settlement is $25,810 and $26,600 as of December 31, 2022 and 2021, respectively, and is included in accounts payable. On July 27, 2020, Brenda Leonhardt filed a lawsuit against U.S. Stem Cell, Inc., Mike Tomas, Dr. William P. Murphy, Jr., Richard T. Spencer, III, Mark Borman, Dr. Samuel S. Ahn, Charles Hart, Sheldon T. Anderson, Greg Knutson, and Kristin Comella in Broward County Court, Case No. CACE-10-012095. The lawsuit alleges breach of a settlement agreement, breach of contract with respect to failure to make a balloon payment under a promissory note, and several tort theories such as misrepresentation and fraudulent transfer. The Company denies most of the allegations in the lawsuit and moved to dismiss almost all of the claims. The motions to dismiss was denied. U.S. Stem Cell, Inc. does note that it provided a promissory note to Ms. Leonhardt, which has not been fully satisfied. The stated due date of the promissory note was June 1, 2020 in the amount of $1,397,762. Mrs. Leonhardt has moved for summary judgment on the note claim but the motion has not yet been set for hearing. The Company, as one of the parties entered into a Settlement Agreement and General Release (the “Agreement”) dated June 3, 2019 related to certain medical procedures. Without admitting any liability, and as part of that Agreement, the Company agreed to provide a five-year 5.25% unsecured promissory note, dated June 15, 2019, in the principal amount of $500,000, payable in monthly increments of $5,000 per month, with a final balloon payment due on June 15, 2024. Accordingly, the Company recognized Pre-litigation expense of $500,000. As of December 31, 2022 and 2021, the remaining carrying value of the note was $403,622 and $413,239, respectively. As of December 31, 2022, the Company is delinquent ten payments and, if not cured, would be considered in default of the promissory note underlying the Agreement. On February 10, 2021, as part of a settlement agreement, the Company transferred its entire member interest in U.S. Stem Cell Clinic, LLC to Dr. Kristin Comella as settlement for $100,000 of accrued interest owed to Dr. Comella (See Note 4, 5 and 6). On February 2, 2023, the Company received a notice of intent to initiate medical malpractice litigation. The Company is reviewing the notice and responding accordingly. The company was one of 11 entities and persons served with the notice. The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of December 31, 2022 other than that described above. Government Claim On May 9, 2018, the U.S. Department of Justice filed an injunctive action, specifically United States of America v. U.S. Stem Clinic, LLC, U.S. Stem Cell, Inc., Kristin C. Comella, and Theodore Gradel. The Complaint alleges, among other matters that the defendants manufacture “stromal vascular fraction” (SVF) products from patient adipose (fat) tissue, which the companies then market as stem cell-based treatments, and which U.S. Stem Cell Clinic, LLC administers to patients, without first obtaining what the government alleges are necessary FDA approvals. Although Theodore Gradel was initially listed as a defendant, he subsequently entered into a consent agreement and is no longer party to this case. The U.S. and the defendants filed cross motions for summary judgment, each asking for a ruling in its favor. On June 3, 2019, the Court entered an order granting Summary Judgment for the government and denying the defendants’ motion for summary judgment. The order focused on the defendants’ actions in providing and marketing SVF therapy. In an order dated June 4, 2019, the Court granted the defendants’ request to allow it the opportunity to work out the language of the form of injunction with the government, and if unsuccessful, to provide a status report to the Court by June 14, 2019, outlining areas of disagreement. The Court further ordered that the defendants (U.S. Stem Clinic, LLC, U.S. Stem Cell, Inc., and Kristin C. Comella) ‘not sell, provide or otherwise engage in any SVF therapy or any other activities to be regulated by the FDA as explained in the Court’s Order on the Parties’ Motions for Summary Judgment.” On June 25, 2019, the Court entered an Order of Permanent Injunction, generally enjoining the defendants with respect to the SVF Product and requiring other actions. The Company filed an appeal on August 23, 2019 and attended oral argument on January 13, 2021. On June 2, 2021, the Eleventh Circuit Court ruled to affirm the lower court’s judgement. The Company is not able to predict the duration, scope, results, or consequences of the U.S. Department of Justice actions and final rulings and management is assessing its options on a going forward basis. The Company, in having divested certain equipment and other assets and assigning its lease, has and will continue to experience a decrease in revenues as the Company both maintains the remainder of the business and transitions into similar or unrelated business opportunities as determined by management. However, management is not able to predict the duration, scope, results, or consequences of the summary judgment and any transition of the business plan. After the Court’s issuance of the Order of Permanent Injunction, the Company has received demand letters for compensation from persons who store their SVF Product and/or other tissue product with the tissue bank (several of the persons have requested refunds of the monies paid to the tissue bank and one person has requested a full refund of monies paid to an altogether separate company due to her not receiving the full amount of treatments she requested; such requests for compensation, to date, have not been material) and requests that the Company preserve cells in the Company’s possession. The Company sought guidance from the Court, which entered an order generally staying the requirement to destroy any SVF Product, pending a decision on the Company’s appeal. However, that appeal has now been concluded and the stay order is no longer in place. In the meanwhile, the Company entered into a transaction to generally divest itself from the tissue bank business. The Company no longer stores any SVF product.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Equity [Text Block]	NOTE 12 STOCKHOLDERS DEFICIT Adjustment to Opening Balances Upon Adoption of ASU 2020-06 Upon adoption of ASU 2020-06 during the first quarter of 2022, the Company adjusted its beginning balance sheet with a decrease in additional paid-in capital of $384,174, offset by a decrease in debt discount on convertible debt of $241,589 and an increase in accumulated deficit of $142,585. Common Stock During the year ended December 31, 2021, the Company issued an aggregate of 6,642,197 shares of its common stock, having a fair value of $231,742, in settlement of outstanding accounts payable. In connection with the issuances, the Company incurred a $151,742 net loss on settlement. During the year ended December 31, 2021, the Company issued 930,916 shares of its common stock, having a fair value of $19,800, in lieu of payment in cash of accrued and unpaid interest of $18,340, resulting in a net loss on settlement of $1,459. During the year ended December 31, 2021, the Company issued an aggregate of 4,000,000 shares of its common stock, having a fair value of $128,000, for services rendered. During the year ended December 31, 2021, convertible notes with an aggregate face value of $375,000 and accrued interest of $586 were converted into an aggregate of 28,891,144 shares of the Company’s common stock (See Note 8 and 9). On September 10, 2021, the Company filing of an Offering Circular on Form 1-A, pursuant to Regulation A (File Number: 024-11617) was qualified by the Securities and Exchange Commission. The Company registered 250,000,000 shares of common stock for maximum proceeds of $2,500,000 (before deducting the maximum broker discount and costs of the offering). During the year ended December 31, 2021, the Company issued 27,500,000 shares of common stock to investors for cash proceeds of $275,000, net of fees and commission, pursuant to the Offering Circular. During the year ended December 31, 2022, the Company issued an aggregate of 6,145,193 shares of its common stock, having a fair value of $48,817, in settlement of outstanding accounts payable of $50,000. In connection with the issuances, the Company incurred a $1,183 net gain on settlement. During the year ended December 31, 2022, the Company issued an aggregate of 2,499,045 shares of its common stock, having a fair value of $19,511, in lieu of accrued interest of $18,340. In connection with the issuances, the Company incurred a $1,171 net loss on settlement. During the year ended December 31, 2022, the Company issued an aggregate of 45,000,000 shares of its common stock to consultants, having a fair value of $297,000, for services to be rendered, which are being amortized to expense over the term of the respective agreements, all of which is 180 days. During the three months ended March 31, 2022, the Company entered into addendums with certain holders owning an aggregate of $214,000 of the convertible notes whereby the conversion price was changed from $0.0266 to $0.008, the maturity date was extended for two years and an aggregate of 53,400,000 commons shares and five-year warrants to purchase 12,500,000 common shares at $0.008 per share were issued, having an aggregate fair value of $491,607. As a result of the changes in the conversion price and the interest rate, the addendums resulted in an extinguishment of $294,000 of the old debt in exchange for new debt with the same face value, having aggregate debt discount of $44,113, and different terms. Accordingly, a loss on debt extinguishment of $447,494 was recognized in the accompanying statements of operations. On February 26, 2022, the Company issued an unsecured convertible promissory note in the principal amount of $27,000 that matures 24 months after the issuance date and 6,750,000 shares of common stock in exchange for proceeds of $27,000. The value ascribed to the common shares was $18,563, which was recognized as debt discount with a corresponding increase in additional paid-in capital. The debt discount of $18,563 is being amortized to interest expense using the effective interest method. On March 23, 2022, a convertible note with a face value of $25,000, having a net book value of $25,000 at the date of conversion, was converted into 3,125,000 shares of the Company’s common stock. As the conversion was at a fixed conversion price, no gain or loss was recognized on conversion (See Note 8). During the year ended December 31, 2022, the Company issued an aggregate of 13,958,334 shares of common stock to investors for cash proceeds of $85,000, net of fees and commission, pursuant to the Offering Circular. Stock Options On April 1, 2013, the Board of Directors approved, subject to subsequently received stockholder approval, the establishment of the Bioheart 2013 Omnibus Equity Compensation Plan, or the “2013 Omnibus Plan” (replacing the 1999 Officers and Employees Stock Option Plan, or the Employee Plan, and the 1999 Directors and Consultants Stock Option Plan). The 2013 Omnibus Plan initially reserved up to fifty thousand (50,000) shares of common stock for issuance. On August 4, 2014, the Board of Directors approved to set the reserve to one hundred thousand (100,000) shares of common stock for issuance and to close the 1999 Officers and Employees Stock Option Plan. On February 2, 2015, at the annual meeting of stockholders, the 2013 Omnibus Equity Compensation Plan was approved. On November 2, 2015, the Company increased the shares reserved under the 2013 Omnibus Plan to five hundred million (500,000,000) shares of common stock for issuance. Effective September 16, 2016, the Company approved an additional twenty five million (25,000,000) shares of common stock to the reserve; effective April 21, 2017, the Company approved an additional twenty five million (25,000,000) shares of common stock to the reserve; effective August 7, 2017, the Company approved an additional thirty million (30,000,000) shares of common stock to the reserve; and effective May 7, 2018, the Company approved an additional one hundred million (100,000,000) shares of common stock to reserve. A summary of the stock option activity for the year ended December 31, 2022 and 2021 is as follows: Weighted Weighted Average Average Number of Exercise Remaining Life Intrinsic Options Price In Years Value Outstanding, December 31, 2020 111,119,914 $ 0.0247 7.2 $ 296,636 Granted - Exercised - Forfeited/Expired (476,030 ) $ 0.0298 Outstanding, December 31, 2021 110,643,884 $ 0.0247 6.3 $ 36,686 Granted - Exercised - Forfeited/Expired (2,500 ) $ 0.1540 Outstanding, December 31, 2022 110,641,384 $ 0.0247 5.3 $ 5,500 Exercisable, December 31, 2022 104,816,384 $ 0.0258 5.2 $ 5,500 Options Outstanding Options Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Options Price In Years Options Price $0.004 to $0.010 41,800,000 $ 0.0051 6.0 35,975,000 $ 0.0051 $0.011 to $0.020 16,250,000 $ 0.0196 3.7 16,250,000 $ 0.0196 $0.021 to $0.030 9,510,000 $ 0.0252 5.9 9,510,000 $ 0.0252 $0.0363 22,635,000 $ 0.0363 4.6 22,635,000 $ 0.0363 $0.0536 20,000,000 $ 0.0536 5.4 20,000,000 $ 0.0536 $0.1540 446,384 $ 0.1540 2.8 446,384 $ 0.1540 110,641,384 $ 0.0247 5.3 104,816,384 $ 0.0258 The aggregate intrinsic value of outstanding stock options was $5,500, based on options with an exercise price less than the Company’s stock price of $0.0048 as of December 31, 2022, which would have been received by the option holders had those option holders exercised their options as of that date. The fair value of all options that vested during the years ended December 31, 2022 and 2021 was $134,974 and $428,556, respectively. As of December 31, 2022, the Company had $22,315 of total unrecognized compensation cost related to non-vested awards granted under the 2013 Omnibus Plan, which the Company expects to recognize over a weighted average period of 0.47 years. Warrants A summary of the warrant activity for the year ended December 31, 2022 and 2021 is as follows: Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2020 1,110,468 $ 12.84 7.1 $ - Granted - Exercised - Expired (7,341 ) $ 77.88 Outstanding, December 31, 2021 1,103,127 $ 12.41 6.2 $ - Granted 12,500,000 0.008 Exercised - Expired (20,000 ) 15.50 Outstanding, December 31, 2022 13,583,127 $ 0.99 4.3 $ - Exercisable, December 31, 2022 13,581,582 $ 0.12 4.3 $ - Warrants Outstanding Warrants Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Warrants Price In Years Warrants Price $0.008 to $0.03 13,500,000 $ 0.01 4.3 13,500,000 $ 0.01 $10.00 to $20.00 61,036 $ 15.22 0.7 61,036 $ 15.22 $20.01 to $30.00 19,543 $ 25.06 1.2 19,543 $ 25.06 $49.86 1,003 $ 49.86 1.2 1,003 $ 49.86 $7,690.00 1,545 $ 7,690.00 4.0 - $ 7,690.00 13,583,127 $ 0.99 4.3 13,581,582 $ 0.12 The aggregate intrinsic value of the issued and exercisable warrants of $-0- represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $0.0048 as of December 31, 2022, which would have been received by the warrant holders had those warrants holders exercised their warrants as of that date.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 13 INCOME TAXES The Company’s provision (benefit) for income taxes consists of the following United States federal and state components: For the Year Ended December 31, 2022 2021 Current: Federal $ - $ - State - - Deferred: Federal 1,263,199 843,633 State 261,362 174,551 1,524,561 1,018,184 Change in valuation allowance (1,524,561 ) (1,018,184 ) Income tax provision (benefit) $ - $ - The deferred tax expense (benefit) is the change in the deferred tax assets and liabilities representing the tax consequences of changes in the amounts of temporary differences, net operating loss carryforwards and changes in tax rates during the year. The Company’s deferred tax assets and liabilities are comprised of the following: December 31, 2022 2021 Deferred tax assets: Net operating losses $ 20,187,838 $ 22,139,733 Share-based compensation 4,405,938 4,371,729 Deferred compensation 1,213,463 1,023,375 Pre-litigation settlement notes payable 157,661 155,710 Accrued interest on deferred compensation 260,012 - Other 154,546 274,703 Total deferred tax assets 26,379,458 27,965,250 Deferred tax liabilities: OID on convertible debt beneficial conversion feature - (61,231 ) Total deferred tax liabilities - (61,231 ) Valuation allowance (26,379,458 ) (27,904,019 ) Total deferred tax assets (liabilities) $ - $ - As of December 31, 2022 and 2021, the Company had U.S. federal net operating loss carryforwards of approximately $79.7 million and $87.4 million, respectively, of which $5.7 million do not expire, but are instead limited to 80% of taxable income in the year utilized. The remaining loss carryforwards expire at various dates from 2023 through 2037. These net operating loss carryforwards may be used to offset future taxable income and thereby reduce the Company’s U.S. federal income taxes. Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by Section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular year. In addition, all or a portion of the Company’s net operating loss carryforwards may expire unutilized. As of December 31, 2022 and 2021, the Company had net operating loss carryforwards for state income tax purposes of approximately $79.7 million and $87.4 million, respectively, of which $5.7 million do not expire, but are instead limited to 80% of taxable income in the year utilized. The remaining loss carryforwards expire at various dates from 2023 through 2037. For U.S. purposes, the Company has not completed its evaluation of NOL utilization limitations under Internal Revenue Code, as amended (the “Code”) Section 382/383, change of ownership rules. If the Company has had a change in ownership, the NOL’s would be limited as to the amount that could be utilized each year, based on the Code or might be eliminated. The Company has provided a full valuation allowance against its net deferred tax assets, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits of these assets will not be realized. The Company complies with the provisions of FASB ASC 740-10 in accounting for its uncertain tax positions. ASC 740-10 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely that not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. Management has determined that the Company has no significant uncertain tax positions requiring recognition under ASC 740-10. The Company is subject to income tax in the U.S., and certain state jurisdictions. The Company has not been audited by the U.S. Internal Revenue Service, or any states in connection with income taxes. The Company’s tax years generally remain open to examination for all federal and state tax matters until its net operating loss carryforwards are utilized and the applicable statutes of limitation have expired. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. The Company recognizes interest and penalties related to unrecognized tax benefits, if incurred, as a component of income tax expense. The significant elements contributing to the difference between the United States federal statutory tax rate and the Company’s effective tax rate are as follows: For the Year Ended December 31, 2022 2021 US federal statutory rate $ (600,168 ) $ (690,357 ) State tax rate, net of federal benefit (92,413 ) (137,277 ) Effect of debt discount on convertible debt (61,231 ) 166,437 Loss on settlement of debt 93,974 - Effect of non-deductible Share-based compensation 52,375 - Other 7,175 26,880 Effect of expiration of net operating loss carryforwards 2,124,849 1,652,501 Change in valuation allowance (1,524,561 ) (1,018,184 ) Income tax provision (benefit) $ - $ -

CONCENTRATIONS

CONCENTRATIONS	12 Months Ended
	Dec. 31, 2022
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	NOTE 14 CONCENTRATIONS Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Generally, the Company’s cash and cash equivalents in interest-bearing accounts does not exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Concentrations of Revenues For the year ended December 31, 2022 and 2021, the following customers accounted for more than 10% of the Company’s net revenues: For the Years Ended December 31, 2022 2021 Customer 1 14 % - Customer 2 12 % - Customer 3 11 % - Customer 4 - 20 % Customer 5 - 17 % Totals 37 % 37 % Concentrations of Accounts Receivable As of December 31, 2022 and 2021, the following customers represented more than 10% of the Company’s accounts receivable: December 31, 2022 2021 Customer 1 95 % 98 % Totals 95 % 98 %

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 15 SUBSEQUENT EVENTS In January 2023, the Company issued an aggregate of 1,125,282 shares of common stock in exchange for services rendered. In March 2023, the Company issued an aggregate 4,000,000 shares of common stock in exchange for services rendered. In April 2023, the Company issued 1,979,412 common shares in exchange for interest.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include stock-based compensation, debt discounts and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable, accrued liabilities, and short-term borrowings, as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts. Credit is extended to customers based on an evaluation of their financial condition, industry reputation, and other judgmental factors considered by the Company’s management. The Company generally does not require collateral or other security interest to support accounts receivable. Based on trends and specific factors, the customer’s credit terms may be modified, including required payment upon delivery. The Company performs regular on-going credit evaluations of its customers as deemed relevant. As events, trends, and circumstance warrant, the Company’s management estimates the amounts that are more likely than not to be uncollectible. These amounts are recognized as bad debt expense and are reflected within selling, general, administrative and other expenses on the Company’s accompanying statements of operations. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. As of December 31, 2022 and 2021, the allowance for doubtful accounts was $75,000.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market with cost being determined on a first-in, first-out (FIFO) basis. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. During the periods presented, there were no inventory write-downs.
Equity Method Investments [Policy Text Block]	Investments The Company follows Accounting Standards Codification subtopic 323-10, Investments-Equity Methods and Joint Ventures (“ASC 323-10”) which requires the accounting for investments where the Company can exert significant influence, but not control of a joint venture or equity investment. The Company accounted for its 49.9% member interest ownership of U.S. Stem Cell Clinic, LLC and its 49% member interest ownership of U.S. Stem Cell Clinic of the Villages utilizing the equity method of accounting (See Note 4).
Revenue [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification Topic 606 “Revenue from Contracts with Customers” (“ASC 606”). ASC 606 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company’s primary sources of revenue are from the sale of test kits and equipment, training services, patient treatments, laboratory services and cell banking. Revenues for kits and equipment sold are not recorded until kits and equipment are received by the customer. Revenues from in-person trainings are recognized when the training occurs and revenues from on demand online trainings are recognized when the customer purchases the rights to the training course. Any cash received as a deposit for trainings are recorded by the Company as a liability. Patient treatments and laboratory services revenue are recognized when those services have been completed or satisfied. Revenues for cell banking are accounted for as multiple performance obligations as described in ASC 606 and addresses accounting for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Because the Company sells its services separately, on more than a limited basis and at a price within a narrow range, the Company was able to allocate revenue based on stand-alone pricing. The multiple performance obligations include stem cell banking, dose retrieval and yearly storage fees. Revenues for stem cell banking and dose retrieval is recognized at the point of service and revenues for the yearly storage fees is recognized over the term of the banking contract, which is typically one year with annual renewals. At December 31, 2022 and 2021, the Company had contract liabilities of $56,500 and $59,500, respectively, all of which relates to the Intellectual Property Licensing Agreement.
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved as defined under the applicable agreement. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company did not incur any research and development expenses during the periods presented.
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For stock-based awards to employees, non-employees and directors, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “if converted” method. The computation of basic and diluted income (loss) per share as excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: December 31, 2022 2021 Options 110,641,384 110,643,884 Warrants 13,583,127 1,103,127 Convertible notes 36,455,827 17,876,880 Total potentially dilutive shares 160,680,338 129,623,891
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In August 2020, the FASB issued ASU 2020-06, which simplifies the guidance on accounting for convertible debt instruments by removing the separation models for: (1) convertible debt with a cash conversion feature; and (2) convertible instruments with a beneficial conversion feature. As a result, the Company will not separately present in equity an embedded conversion feature in such debt. Instead, we will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. We expect the elimination of these models will reduce reported interest expense and increase reported net income for the Company’s convertible instruments falling under the scope of those models before the adoption of ASU 2020-06. Also, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The Company adopted ASU 2020-06 in the first quarter of 2022 utilizing the modified retrospective method. As a result, the Company adjusted its beginning balance sheet with a decrease in additional paid-in capital of $384,174, offset by a decrease in debt discount on convertible debt of $241,589 and an increase in accumulated deficit of $142,585. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments”, which significantly changes how entities will measure credit losses for most financial assets, including accounts receivable. ASU No. 2016-13 will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. On November 15, 2019, the FASB delayed the effective date of Topic 326 for certain small public companies and other private companies until fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and not-for-profit entities. The Company does not expect the new guidance will have a material impact on its financial statements. There are various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net loss per share are as follows: December 31, 2022 2021 Options 110,641,384 110,643,884 Warrants 13,583,127 1,103,127 Convertible notes 36,455,827 17,876,880 Total potentially dilutive shares 160,680,338 129,623,891

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses consisted of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank $ 756,437 $ 644,670 Accrued interest payable 1,746,990 1,227,588 Vendor accruals and other 79,132 79,132 Total Accrued expenses $ 2,582,559 $ 1,951,390

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2022
Debt Disclosure [Abstract]
Schedule of Debt [Table Text Block]	Notes payable were comprised of the following as of December 31, 2022 and 2021: December 31, 2022 2021 Seaside Bank note payable $ 980,000 $ 980,000 Dr. Comella note payable* 255,579 255,579 Dr. Comella note payable* 300,000 300,000 Dr. Comella note payable* 300,000 300,000 Dr. Comella note payable* 300,000 300,000 Hunton & Williams note payable 373,500 380,000 Weider note payable 403,622 413,239 Mallard note payable 223,000 232,750 EIDL note payable 150,000 150,000 Total notes payable 3,285,701 3,311,568 Less unamortized debt discount (21,574 ) (31,627 ) Total notes payable net of unamortized debt discount 3,264,127 3,279,941 Less current portion (2,582,083 ) (2,557,881 ) Long-term portion $ 682,044 $ 722,060 * Dr. Comella is a former member of the Board of Directors and resigned on December 1, 2019.

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Schedule of Related Party Transactions [Table Text Block]	At December 31, 2022 and 2021, accrued interest on the notes was $770,585 and $612,323, respectively, and is included in accrued expenses on the accompanying balance sheet. December 31, 2022 2021 Northstar $ 262,000 $ 262,000 Note payable, Mr. Tomas 161,786 161,786 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 178,077 178,077 Note payable, Mr. Tomas 187,500 187,500 Note payable, Mr. Tomas 187,500 187,500 Note payable, Mr. Tomas 500,000 500,000 Note payable, Mr. Tomas 100,962 100,962 Note payable, Mr. Tomas 143,653 143,653 Note payable, Mr. Tomas 90,991 90,991 Note payable, Mr. Tomas 43,269 43,269 Note payable, Mr. Tomas 187,500 187,500 Note payable, Mr. Tomas 100,962 100,962 Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Note payable, Mr. Tomas 187,500 - Total notes payable - related parties $ 3,894,200 $ 3,144,200

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Lease, Cost [Table Text Block]	In October 2019, the Company relocated to a new location within the same city and entered into a month-to-month lease. During the year ended December 31, 2022 and 2021, lease expense was comprised of the following: For the Years Ended December 31, 2022 2021 Operating lease expense $ 6,541 $ 4,711 Total lease expense $ 6,541 $ 4,711

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	12 Months Ended
	Dec. 31, 2022
Stockholders' Equity Note [Abstract]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	A summary of the stock option activity for the year ended December 31, 2022 and 2021 is as follows: Weighted Weighted Average Average Number of Exercise Remaining Life Intrinsic Options Price In Years Value Outstanding, December 31, 2020 111,119,914 $ 0.0247 7.2 $ 296,636 Granted - Exercised - Forfeited/Expired (476,030 ) $ 0.0298 Outstanding, December 31, 2021 110,643,884 $ 0.0247 6.3 $ 36,686 Granted - Exercised - Forfeited/Expired (2,500 ) $ 0.1540 Outstanding, December 31, 2022 110,641,384 $ 0.0247 5.3 $ 5,500 Exercisable, December 31, 2022 104,816,384 $ 0.0258 5.2 $ 5,500
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Options Outstanding Options Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Options Price In Years Options Price $0.004 to $0.010 41,800,000 $ 0.0051 6.0 35,975,000 $ 0.0051 $0.011 to $0.020 16,250,000 $ 0.0196 3.7 16,250,000 $ 0.0196 $0.021 to $0.030 9,510,000 $ 0.0252 5.9 9,510,000 $ 0.0252 $0.0363 22,635,000 $ 0.0363 4.6 22,635,000 $ 0.0363 $0.0536 20,000,000 $ 0.0536 5.4 20,000,000 $ 0.0536 $0.1540 446,384 $ 0.1540 2.8 446,384 $ 0.1540 110,641,384 $ 0.0247 5.3 104,816,384 $ 0.0258
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the year ended December 31, 2022 and 2021 is as follows: Weighted Weighted Average Average Remaining Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2020 1,110,468 $ 12.84 7.1 $ - Granted - Exercised - Expired (7,341 ) $ 77.88 Outstanding, December 31, 2021 1,103,127 $ 12.41 6.2 $ - Granted 12,500,000 0.008 Exercised - Expired (20,000 ) 15.50 Outstanding, December 31, 2022 13,583,127 $ 0.99 4.3 $ - Exercisable, December 31, 2022 13,581,582 $ 0.12 4.3 $ -
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	Warrants Outstanding Warrants Exercisable Weighted Weighted Weighted Outstanding Average Average Exercisable Average Exercise Number of Exercise Remaining Life Number of Exercise Price Warrants Price In Years Warrants Price $0.008 to $0.03 13,500,000 $ 0.01 4.3 13,500,000 $ 0.01 $10.00 to $20.00 61,036 $ 15.22 0.7 61,036 $ 15.22 $20.01 to $30.00 19,543 $ 25.06 1.2 19,543 $ 25.06 $49.86 1,003 $ 49.86 1.2 1,003 $ 49.86 $7,690.00 1,545 $ 7,690.00 4.0 - $ 7,690.00 13,583,127 $ 0.99 4.3 13,581,582 $ 0.12

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The Company’s provision (benefit) for income taxes consists of the following United States federal and state components: For the Year Ended December 31, 2022 2021 Current: Federal $ - $ - State - - Deferred: Federal 1,263,199 843,633 State 261,362 174,551 1,524,561 1,018,184 Change in valuation allowance (1,524,561 ) (1,018,184 ) Income tax provision (benefit) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The deferred tax expense (benefit) is the change in the deferred tax assets and liabilities representing the tax consequences of changes in the amounts of temporary differences, net operating loss carryforwards and changes in tax rates during the year. The Company’s deferred tax assets and liabilities are comprised of the following: December 31, 2022 2021 Deferred tax assets: Net operating losses $ 20,187,838 $ 22,139,733 Share-based compensation 4,405,938 4,371,729 Deferred compensation 1,213,463 1,023,375 Pre-litigation settlement notes payable 157,661 155,710 Accrued interest on deferred compensation 260,012 - Other 154,546 274,703 Total deferred tax assets 26,379,458 27,965,250 Deferred tax liabilities: OID on convertible debt beneficial conversion feature - (61,231 ) Total deferred tax liabilities - (61,231 ) Valuation allowance (26,379,458 ) (27,904,019 ) Total deferred tax assets (liabilities) $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The significant elements contributing to the difference between the United States federal statutory tax rate and the Company’s effective tax rate are as follows: For the Year Ended December 31, 2022 2021 US federal statutory rate $ (600,168 ) $ (690,357 ) State tax rate, net of federal benefit (92,413 ) (137,277 ) Effect of debt discount on convertible debt (61,231 ) 166,437 Loss on settlement of debt 93,974 - Effect of non-deductible Share-based compensation 52,375 - Other 7,175 26,880 Effect of expiration of net operating loss carryforwards 2,124,849 1,652,501 Change in valuation allowance (1,524,561 ) (1,018,184 ) Income tax provision (benefit) $ - $ -

CONCENTRATIONS (Tables)

CONCENTRATIONS (Tables)	12 Months Ended
	Dec. 31, 2022
Customer Concentration Risk [Member]
CONCENTRATIONS (Tables) [Line Items]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	For the year ended December 31, 2022 and 2021, the following customers accounted for more than 10% of the Company’s net revenues: For the Years Ended December 31, 2022 2021 Customer 1 14 % - Customer 2 12 % - Customer 3 11 % - Customer 4 - 20 % Customer 5 - 17 % Totals 37 % 37 %
Credit Concentration Risk [Member]
CONCENTRATIONS (Tables) [Line Items]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	As of December 31, 2022 and 2021, the following customers represented more than 10% of the Company’s accounts receivable: December 31, 2022 2021 Customer 1 95 % 98 % Totals 95 % 98 %

GOING CONCERN AND MANAGEMENT'_2

GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and Cash Equivalents, at Carrying Value	$ 5,133	$ 39,393
Working Capital (Deficit)	(14,009,852)
Net Income (Loss) Attributable to Parent	(2,857,943)	(3,287,416)
Net Cash Provided by (Used in) Operating Activities	$ (304,852)	$ (1,057,939)

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Jan. 30, 2018
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Accounts Receivable, Allowance for Credit Loss	$ 75,000
Deferred Revenue	56,500	$ 59,500
Adjustments to Additional Paid in Capital, Other	384,174	$ 0
Convertible Debt Discount Increase Decrease	241,589
Retained Earnings Increase Decrease	$ 142,585
U.S. Stem Cell Clinic, LLC [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.90%
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49%		49%

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	160,680,338	129,623,891
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	110,641,384	110,643,884
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13,583,127	1,103,127
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	36,455,827	17,876,880

INVESTMENTS (Details)

INVESTMENTS (Details) - USD ($)		12 Months Ended				281 Months Ended
	Jan. 30, 2018	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2022	Jan. 29, 2019
U.S. Stem Cell Clinic, LLC [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage		49.90%				49.90%
Income (Loss) from Equity Method Investments		$ 0				$ 599,721
Proceeds from Equity Method Investment, Distribution		0	$ 0			663,870
Equity Method Investments		0	0			0
Accounts Receivable, after Allowance for Credit Loss		0	28,763			0
Revenues		0	2,531
Regenerative Wellness Clinic, LLC [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage							33.30%
Equity Method Investments		$ 0	0			$ 0
U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
INVESTMENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49%	49%				49%
Income (Loss) from Equity Method Investments		$ 0				$ 23,050
Proceeds from Equity Method Investment, Distribution		0	0
Revenues		0	0
Related Party Transaction, Description of Transaction	To that end, U.S. Stem Cell Clinic of The Villages LLC (the “Villages”) was formed January 30, 2018. Knutson provided the Company with the sum of Three Hundred Thousand Dollars ($300,000) (the “Investment”) to be utilized for the formation and initial operation of the Villages. Currently, Knutson holds a 51% member interest in the Villages and the Company holds a 49% member interest. The Company will provide operating assistance as well as management services, the latter to be compensated at fee of five percent (5%) of the Villages gross revenues
Ownership Percentage by Knutson	51%
Proceeds from Contributed Capital				$ 86,750	$ 189,909
Accounts Receivable, before Allowance for Credit Loss		0	0			$ 0
Proceeds from Fees Received		$ 0	$ 0
Utilized for Fromation of LLC [Member] | U.S. Stem Cell Clinic of The Village LLC (the "LLC") [Member]
INVESTMENTS (Details) [Line Items]
Related Party Transaction, Amounts of Transaction	$ 300,000

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)							3 Months Ended	12 Months Ended
	Oct. 01, 2022	Apr. 05, 2022	Oct. 01, 2021	Apr. 01, 2021	Feb. 10, 2021	Oct. 01, 2020	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Proceeds from Sale of Long-Term Investments					$ 100,000
Gain (Loss) on Extinguishment of Debt	$ 450	$ 722	$ 274	$ (1,734)	$ 100,000	$ (984)	$ 447,494	$ (447,494)	$ 0

ACCRUED EXPENSES (Details) - Sc

ACCRUED EXPENSES (Details) - Schedule of Accrued Liabilities - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Accrued Liabilities Abstract
Interest and fees payable to the Guarantors of the Company’s loan agreement with Seaside Bank	$ 756,437	$ 644,670
Accrued interest payable	1,746,990	1,227,588
Vendor accruals and other	79,132	79,132
Total Accrued expenses	$ 2,582,559	$ 1,951,390

NOTES PAYABLE (Details)

NOTES PAYABLE (Details)																1 Months Ended	3 Months Ended			12 Months Ended
	Oct. 01, 2022 USD ($)	Apr. 05, 2022 USD ($)	Oct. 01, 2021 USD ($)	Apr. 01, 2021 USD ($)	Feb. 10, 2021 USD ($)	Oct. 01, 2020 USD ($)	Jun. 20, 2020 USD ($)	Feb. 05, 2020 USD ($)	Dec. 06, 2019 USD ($)	Jun. 15, 2019 USD ($)	Jun. 03, 2019 USD ($)	May 07, 2018 USD ($)	Aug. 31, 2017 USD ($)	Aug. 07, 2017 USD ($)	Jun. 01, 2015	Mar. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2018	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2016 USD ($)	Feb. 26, 2022 USD ($)	Jun. 01, 2020 USD ($)	Jul. 01, 2019 USD ($)	Sep. 06, 2016 USD ($)	Oct. 25, 2010 USD ($)
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount								$ 35,000		$ 500,000													$ 25,000
Debt Instrument, Interest Rate, Stated Percentage								5%		5.25%						0%	0%
Debt Instrument, Maturity Date								Feb. 05, 2021
Notes Payable																		$ 3,144,200		$ 3,894,200	$ 3,144,200			$ 1,397,762
Proceeds from Sale of Long-Term Investments					$ 100,000
Gain (Loss) on Extinguishment of Debt	$ 450	$ 722	$ 274	$ (1,734)	$ 100,000	$ (984)											$ 447,494			(447,494)	0
Interest Payable																		166,424		224,203	166,424
Repayments of Long-Term Debt																		1,500			6,000
Debt Instrument, Unamortized Discount																$ 44,113	$ 44,113
Debt Instrument, Periodic Payment										$ 5,000
Litigation Settlement, Expense																					500,000
Repayments of Notes Payable																				17,618	52,238
Amortization of Debt Discount (Premium)																				685,326	977,386
Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount																		31,627		21,574	31,627
Seaside National Bank and Trust [Member] | Notes Payable to Banks [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount																											$ 980,000
Debt Instrument, Interest Rate, Stated Percentage																											4.25%
Debt Instrument, Maturity Date																			May 18, 2020
Comella Note #1 [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount																										$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																										5%
Notes Payable																				255,579
Comella Note #2 [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount														$ 300,000
Debt Instrument, Interest Rate, Stated Percentage														5%
Notes Payable																				300,000
Debt Instrument, Term														1 year
Comella Note #3 [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount												$ 300,000
Debt Instrument, Interest Rate, Stated Percentage												5%
Notes Payable																				300,000
Debt Instrument, Term												6 months
Comella Note #4 [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount																									$ 300,000
Debt Instrument, Interest Rate, Stated Percentage																									5%
Notes Payable																				300,000
Hunton & Williams Notes [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																						8%
Notes Payable																		380,000		373,500	380,000
Number of Outstanding Notes Payable																						2
Debt Instrument, Payment Terms													payable in one balloon payment upon the date of a written demand and upon certain triggering events occurring									payable in one balloon payment upon the date the Noteholder provides written demand, however the Company is not obligated to make payments until the Northstar Biotech Group, LLC (or successor) Loan is paid off.
Other Notes Payable													$ 747,680
Accounts Payable, Other, Current													40,596
Notes and Loans Payable													$ 788,276
Debt Instrument, Description													The noteholder agreed to accept full payment of their obligation over a four (4) year period in 48 monthly installments on an adjusted debt obligation in aggregate of $624,000 (reducing the outstanding balance), with such payments staggered in amounts such that the Company will pay $10,000 monthly the first year, $12,000 monthly the second year, $14,000 monthly the third year, and $16,000 monthly the final year. In addition, the noteholder agreed to suspend accrual interest on the notes commencing September 1, 2017. The Agreement remains in full force and effect provided the Company continues to make the monthly payments, there is no event of default as defined in the notes and an agreement to a subordination agreement by Northstar Biotech Group, LLC, which has been provided. In May 2019, the Company did not make the required scheduled payment. In September 2019, the noteholder agreed to waive their default rights under the agreement provided a minimum of $5,000 was paid by the end of 2019 and to reduce the required monthly payment to $500 per month commencing in January 2020. The Company satisfied the $5,000 payment requirement by the end of 2019 and commenced making the required $500 monthly payments in January 2020. The Company last made a $500 payment in March 2021 and thereby became delinquent until making three $1,500 payments during the fourth quarter of 2021 (a total of $6,000 in payments were made during 2021) thereby becoming current as of December 31, 2021.
Imputed Interest, Rate													5%
Debt Instrument, Unamortized Discount													$ 69,700
Hunton & Williams Note #1 [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Notes Payable																						$ 61,150
Hunton & Williams Note #2 [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Notes Payable																						$ 323,822
Weider promissory note [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount											$ 500,000
Debt Instrument, Interest Rate, Stated Percentage											5.25%
Notes Payable																		413,239		403,622	413,239
Interest Payable																		1,808		17,014	1,808
Debt Instrument, Periodic Payment											$ 5,000
Litigation Settlement, Expense											$ 500,000
Repayments of Notes Payable																$ 5,000
Note Payable, Settlement of Subordinated Debt, Accrued Interest and Guarantor Fees [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Interest Rate Terms															non-interest bearing
Mallard Note Payable [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount									$ 250,000
Debt Instrument, Interest Rate, Stated Percentage									5%
Notes Payable																		201,123		201,426	201,123
Debt Instrument, Payment Terms									payable in monthly increments of $750 per month, with a final balloon payment of $205,000 due on January 1, 2025
Debt Instrument, Unamortized Discount									$ 51,063									31,627		21,574	31,627
Debt Instrument, Periodic Payment																				750
Litigation Settlement, Expense									$ 198,937
Repayments of Debt																				8,250
Amortization of Debt Discount (Premium)																				10,052	9,610
EIDL Note Payable [Member] | Notes Payable, Other Payables [Member]
NOTES PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount							$ 150,000
Debt Instrument, Interest Rate, Stated Percentage							3.75%
Notes Payable																				150,000
Interest Payable																		$ 8,615		$ 13,509	$ 8,615
Debt Instrument, Payment Terms							Installment payments, including principal and interest, are due monthly beginning June 20, 2021 (twelve months from the date of the SBA Loan Agreement) in the amount of $731. On March 15, 2021, the initial payment date was extended 12 months to June 20, 2022. On March 15, 2022, the initial payment date was extended 6 months to December 20, 2022. The balance of principal and interest is payable thirty years from the date of the SBA Loan Agreement.
Debt Instrument, Periodic Payment							$ 731

NOTES PAYABLE (Details) - Sched

NOTES PAYABLE (Details) - Schedule of Debt - Notes Payable, Other Payables [Member] - USD ($)		Dec. 31, 2022	Dec. 31, 2021	Dec. 06, 2019	Aug. 31, 2017
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross		$ 3,285,701	$ 3,311,568
Less unamortized debt discount		(21,574)	(31,627)
Total notes payable net of unamortized debt discount		3,264,127	3,279,941
Less current portion		(2,582,083)	(2,557,881)
Long term portion		682,044	722,060
Seaside National Bank and Trust [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross		980,000	980,000
Comella Note #1 [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	[1]	255,579	255,579
Comella Note #2 [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	[1]	300,000	300,000
Comella Note #3 [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	[1]	300,000	300,000
Comella Note #4 [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross	[1]	300,000	300,000
Hunton & Williams Notes [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross		373,500	380,000
Less unamortized debt discount					$ (69,700)
Weider promissory note [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross		403,622	413,239
Mallard Note Payable [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross		223,000	232,750
Less unamortized debt discount		(21,574)	(31,627)	$ (51,063)
EIDL Note Payable [Member]
NOTES PAYABLE (Details) - Schedule of Debt [Line Items]
Notes Payable, Gross		$ 150,000	$ 150,000
[1]Dr. Comella is a former member of the Board of Directors and resigned on December 1, 2019.

PROMISSORY NOTE PAYABLE (Detail

PROMISSORY NOTE PAYABLE (Details) - Promissory Note [Member] - USD ($)			12 Months Ended
	Jun. 01, 2020	Jun. 01, 2015	Dec. 31, 2022	Dec. 31, 2021
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount		$ 1,697,762
Debt Instrument, Periodic Payment		$ 75,000
Default Interest Rate	18%
Imputed Interest, Rate		5%
Debt Instrument, Unamortized Discount		$ 368,615
Notes Payable			$ 1,397,762	$ 1,397,762
Amortization of Debt Discount (Premium)			$ 650,017	$ 398,420
Unpaid Guarantor Fees [Member]
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount		624,737
Principal [Member]
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount		1,500,000
Interest [Member]
PROMISSORY NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Original Debt, Amount		$ 373,469

CONVERTIBLE NOTE PAYABLE (Detai

CONVERTIBLE NOTE PAYABLE (Details) - USD ($)																					3 Months Ended	12 Months Ended
	Oct. 01, 2022	Apr. 05, 2022	Mar. 31, 2022	Mar. 11, 2022	Feb. 26, 2022	Nov. 09, 2021	Oct. 29, 2021	Oct. 01, 2021	Jul. 30, 2021	Jun. 20, 2021	Apr. 08, 2021	Apr. 01, 2021	Mar. 24, 2021	Mar. 23, 2021	Feb. 26, 2021	Feb. 10, 2021	Oct. 01, 2020	Sep. 08, 2020	Feb. 05, 2020	Oct. 07, 2015	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Jun. 15, 2019
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Convertible Debt Discount Increase Decrease																						$ 241,589
Debt Instrument, Face Amount					$ 25,000														$ 35,000						$ 500,000
Debt Instrument, Maturity Date																			Feb. 05, 2021
Debt Instrument, Interest Rate, Stated Percentage			0%																5%		0%				5.25%
Debt Instrument, Convertible, Terms of Conversion Feature																			right to convert the outstanding balance of the note at any time into shares of common stock of the Company at a conversion price equal to a thirty percent (30%) discount of the average closing price of the Company’s common stock on the OTC Markets electronic exchange for the prior thirty (30) trading days prior to conversion
Debt Instrument, Unamortized Discount			$ 44,113																		$ 44,113
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,377,891	1,121,154	6,750,000	3,125,000	3,125,000			743,341				187,575		7,518,797			2,035,820			34,522			28,891,144
Amortization of Debt Discount (Premium)																						685,326	$ 977,386
Interest Payable																						224,203	166,424
Debt Conversion, Converted Instrument, Amount	$ 9,645	$ 9,866			$ 25,000			$ 8,921				$ 10,879
Debt Instrument, Convertible, Beneficial Conversion Feature																						$ 0	$ 641,688
Debt Instrument, Repurchased Face Amount			$ 214,000																		$ 214,000
Debt Instrument, Maturity Date, Description																					extended for two years
Stock Issued During Period, Shares, New Issues (in Shares)																					53,400,000	13,958,334	27,500,000
Class of Warrant or Rights, Granted (in Shares)																					12,500,000	12,500,000	0
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																						$ 0.99	$ 12.41	$ 12.84
Adjustments to Additional Paid in Capital, Warrant Issued																					$ 491,607
Debt Instrument, Interest Rate, Increase (Decrease)																					12%
Extinguishment of Debt, Amount																					$ 294,000
Debt Conversion, Original Debt, Amount			27,000	$ 25,000								9,145								$ 100,000		$ 25,000	$ 375,586
Gain (Loss) on Extinguishment of Debt	$ 450	$ 722						$ 274				$ (1,734)				$ 100,000	$ (984)				447,494	(447,494)	0
Repayments of Convertible Debt																						10,000	0
Debt Instrument, Debt Default, Amount																						115,000
Principal [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount																							375,000
Interest [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount																							586
Debt Conversion, Original Debt, Amount																						18,340	18,340
Gain (Loss) on Extinguishment of Debt																						1,171	1,459
Convertible Notes Payable [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Unamortized Discount																			$ 15,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)									3,804,348
Amortization of Debt Discount (Premium)																						0	1,874
Convertible Notes Payable			294,000																		294,000	0	419,000
Debt Instrument, Repurchased Face Amount			$ 80,000																		80,000
Extinguishment of Debt, Amount																					$ 294,000
Convertible Note, March 24, 2021 [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount													$ 110,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)						15,741,286
Amortization of Debt Discount (Premium)																							110,000
Convertible Notes Payable																						0
Interest Payable																						0
Debt Instrument, Convertible, Conversion Price (in Dollars per share)													$ 0.007
Debt Instrument, Term													12 months
Debt Instrument, Convertible, Beneficial Conversion Feature													$ 110,000
Note September 8, 2020 [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount																		$ 10,000
Debt Instrument, Interest Rate, Stated Percentage																		5%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)						226,713
Convertible Notes Payable																						0
Interest Payable																						0
Debt Instrument, Convertible, Conversion Price (in Dollars per share)																		$ 0.0467
Default Interest Rate																		18%
Note September 8, 2020 [Member] | Principal [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount						$ 10,000
Note September 8, 2020 [Member] | Interest [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount						$ 588
Convertible Note, February 26, 2021 [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount											$ 200,000				$ 619,000
Debt Instrument, Unamortized Discount																						37,224	0
Debt Conversion, Converted Instrument, Shares Issued (in Shares)											7,518,797
Amortization of Debt Discount (Premium)																						25,451	141,586
Convertible Notes Payable																						373,775
Debt Instrument, Convertible, Conversion Price (in Dollars per share)			$ 0.0266												$ 0.0266						$ 0.0266
Debt Instrument, Term															12 months
Debt Instrument, Convertible, Beneficial Conversion Feature															$ 521,850
Common Stock, Convertible, Conversion Price, Decrease (in Dollars per share)																					$ 0.008
Debt Instrument, Maturity Date, Description																					extended for two years
Stock Issued During Period, Shares, New Issues (in Shares)																					53,400,000
Class of Warrant or Rights, Granted (in Shares)																					12,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 0.008																		$ 0.008
Adjustments to Additional Paid in Capital, Warrant Issued																					$ 491,607
Convertible Note, June 20, 2021 [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount										$ 20,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)						1,600,000
Amortization of Debt Discount (Premium)																							$ 2,400
Convertible Notes Payable																						0
Debt Instrument, Convertible, Conversion Price (in Dollars per share)										$ 0.0125
Debt Instrument, Term										12 months
Debt Instrument, Convertible, Beneficial Conversion Feature										$ 2,400
Convertible Note, October 29, 2021 [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount							$ 17,000
Amortization of Debt Discount (Premium)							$ 998
Debt Instrument, Convertible, Conversion Price (in Dollars per share)							$ 0.008
Debt Instrument, Term							12 years
Debt Instrument, Convertible, Beneficial Conversion Feature							$ 7,438
Convertible Debt [Member]
CONVERTIBLE NOTE PAYABLE (Details) [Line Items]
Debt Instrument, Face Amount			$ 214,000												$ 200,000						$ 214,000
Convertible Notes Payable																						$ 17,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)			$ 0.0266																		$ 0.0266

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)																																		3 Months Ended	12 Months Ended
	Oct. 01, 2022	Apr. 05, 2022	Mar. 31, 2022	Mar. 11, 2022	Feb. 26, 2022	Oct. 01, 2021	Apr. 01, 2021	Mar. 23, 2021	Feb. 10, 2021	Oct. 01, 2020	Apr. 01, 2020	Feb. 05, 2020	Oct. 01, 2019	Jul. 01, 2019	Oct. 19, 2018	May 07, 2018	Apr. 19, 2018	Oct. 02, 2017	Apr. 01, 2017	Mar. 09, 2017	Nov. 09, 2016	Oct. 06, 2016	Apr. 07, 2016	Oct. 07, 2015	Oct. 02, 2015	Apr. 03, 2015	Oct. 03, 2014	Apr. 02, 2014	Dec. 24, 2013	Sep. 30, 2013	Oct. 01, 2012	Sep. 21, 2012	Mar. 30, 2012	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2013	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Feb. 26, 2021	Dec. 31, 2020	Sep. 30, 2020	Jul. 01, 2020	Jun. 30, 2020	Jun. 01, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 15, 2019	Aug. 07, 2017	Dec. 31, 2015	Feb. 28, 2013	Feb. 29, 2012
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Other Liabilities, Current																																			$ 1,137,642	$ 951,432
Debt Instrument, Face Amount					$ 25,000							$ 35,000																																							$ 500,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,377,891	1,121,154	6,750,000	3,125,000	3,125,000	743,341	187,575	7,518,797		2,035,820														34,522												28,891,144
Class of Warrant or Rights, Granted (in Shares)																																		12,500,000	12,500,000	0
Percentage of Revenues to be Received as Royalty																					5%
Debt Instrument, Interest Rate, Stated Percentage			0%									5%																						0%																	5.25%
Preferred Stock, Shares Authorized (in Shares)																																			20,000,000	20,000,000																	20,000,000
Debt Conversion, Original Debt, Amount			$ 27,000	$ 25,000			$ 9,145																	$ 100,000											$ 25,000	$ 375,586
Debt Conversion, Converted Instrument, Amount	$ 9,645	$ 9,866			$ 25,000	$ 8,921	10,879
Stock Issued During Period, Value, Other																																			48,817	231,742
Paid-in-Kind Interest	9,195	9,144				9,195				$ 9,195																									19,511	19,800
Gain (Loss) on Extinguishment of Debt	$ 450	$ 722				$ 274	$ (1,734)		$ 100,000	(984)																								$ 447,494	(447,494)	0
Stock Issued During Period, Value, Conversion of Convertible Securities										$ 10,179
Notes Payable																																			3,894,200	3,144,200												$ 1,397,762
Debt Instrument, Maturity Date												Feb. 05, 2021
Interest Payable																																			224,203	166,424
Interest [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Original Debt, Amount																																			$ 18,340	18,340
Debt Conversion, Converted Instrument, Amount																																				$ 586
Stock Issued During Period, Shares, Other (in Shares)																																			2,499,045	930,916
Stock Issued During Period, Value, Other																																			$ 19,511	$ 19,800
Gain (Loss) on Extinguishment of Debt																																			1,171	1,459
Northstar Claims [Member] | Stock Issued for Conversion of Series A Preferred Stock and Litigation Case [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)																			1,000,000	30,000,000
Convertible Debt [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount			$ 214,000																															$ 214,000									$ 200,000
Series A Preferred Stock [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Preferred Stock, Voting Rights																															modify the voting rights of the subsequently cancelled Series A Convertible Preferred Stock from 20 votes per share on matters to be voted on by the common stockholders to 25 votes per share on matters to be voted on by the common stockholders and all prior and subsequent payments of interest will be in common stock
Officers and Directors [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Proceeds from Related Party Debt																																			186,210	90,000
Other Liabilities, Current																																			1,137,642	951,432
Affiliated Entity [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																																							$ 544,267
Debt Conversion, Converted Instrument, Shares Issued (in Shares)											1,445,647		1,692,353		164,523		379,141	559,187	286,315										3,916	8,772
Debt Instrument, Payment Terms																															Company was obligated to issue additional preferred stock equal in lieu of payment of cash of accrued and unpaid interest on each six-month anniversary of the effective date (October 1, 2012).		agreed to extend until May 1, 2012 the initial payment date for any and all required monthly under the Note, such that the first of the four monthly payments required under the Note will be due and payable on May 1, 2012 and all subsequent payments will be due on a monthly basis thereafter commencing on June 1, 2012, and to waive any and all defaults and/or events of default under the Note with respect to such payments. The Company did not make the required payment, and as a result, was in default of the revised agreement. The Company renegotiated the terms of the Note and Northstar agreed to suspend the requirement of principal payments by the Company and allow payment of interest-only in common stock.
Class of Warrant or Rights, Granted (in Shares)																																5,000
Debt Instrument, Debt Default, Description of Violation or Event of Default																															entered into a limited waiver and forbearance agreement providing a recapitalized new note balance comprised of all sums due Northstar with a maturity date extended perpetually. The Company agreed to issue 5,000,000 shares of Series A Convertible Preferred Stock and 10,000 shares of common stock in exchange for $210,000 as payment towards outstanding debt, default interest, penalties, professional fees outstanding and due Northstar. In addition, the Company executed a security agreement granting Northstar a lien on all patents, patent applications, trademarks, service marks, copyrights and intellectual property rights of any nature, as well as the results of all clinical trials, know-how for preparing Myoblasts, old and new clinical data, existing approved trials, all right and title to Myoblasts, clinical trial protocols and other property rights.In addition, the Company granted Northstar a perpetual license on products as described for resale, relicensing, and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated.
Percentage of Revenues to be Received as Royalty																															8%
Debt Instrument, Interest Rate, Stated Percentage																															12.85%																							7%
Debt Conversion, Original Debt, Amount											$ 9,145						$ 9,145	$ 12,705	$ 12,703										$ 85,447	$ 100,000
Debt Conversion, Converted Instrument, Amount											11,565
Paid-in-Kind Interest													$ 9,195		$ 9,195
Gain (Loss) on Extinguishment of Debt											$ 2,420
Notes Payable																																			262,000
Affiliated Entity [Member] | Notes Payable, Other Payables [Member] | Interest [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued (in Shares)																						848,490	57,778		4,156	1,363	515	275
Debt Conversion, Original Debt, Amount																						$ 12,705			$ 12,705	$ 12,635	$ 12,705	$ 12,635
Debt Conversion, Converted Instrument, Amount																							$ 12,705
Affiliated Entity [Member] | Series A Preferred Stock [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Value, Other																																					$ 316,800
Chief Executive Officer [Member] | Note Payable #5 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																																				$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																																																				5%
Notes Payable																																			161,786	161,786
Chief Executive Officer [Member] | Note Payable #6 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																5%
Notes Payable																																			500,000	500,000
Debt Instrument, Term																6 months
Chief Executive Officer [Member] | Note Payable #7 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount														$ 500,000
Debt Instrument, Interest Rate, Stated Percentage														5%
Notes Payable																																			500,000	500,000
Chief Executive Officer [Member] | Note Payable #8 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Interest Rate, Stated Percentage																																																		5%
Notes Payable																																			178,077	178,077
Chief Executive Officer [Member] | Note Payable #9 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																																	$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																																	5%
Notes Payable																																			187,500	187,500
Chief Executive Officer [Member] | Note Payable #10 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																															$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																															5%
Notes Payable																																			187,500	187,500
Chief Executive Officer [Member] | Note Payable #11 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																														$ 500,000
Debt Instrument, Interest Rate, Stated Percentage																																														5%
Notes Payable																																			500,000	500,000
Chief Executive Officer [Member] | Note Payable #12 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																													$ 100,962
Debt Instrument, Interest Rate, Stated Percentage																																													5%
Notes Payable																																			100,962	100,962
Chief Executive Officer [Member] | Note Payable #13 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																												$ 143,654
Debt Instrument, Interest Rate, Stated Percentage																																												5%
Notes Payable																																			143,653	143,653
Chief Executive Officer [Member] | Note Payable #14 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																										$ 90,990
Debt Instrument, Interest Rate, Stated Percentage																																										5%
Notes Payable																																			90,991	90,991
Chief Executive Officer [Member] | Note Payable #15 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																									$ 43,269
Debt Instrument, Interest Rate, Stated Percentage																																									5%
Notes Payable																																			43,269	43,269
Chief Executive Officer [Member] | Note Payable #16 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																								$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																								5%
Notes Payable																																			187,500	187,500
Chief Executive Officer [Member] | Note Payable #17 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																				$ 100,962
Debt Instrument, Interest Rate, Stated Percentage																																				5%
Notes Payable																																			100,962	$ 100,962
Chief Executive Officer [Member] | Note Payable #18 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																			$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																			5%
Notes Payable																																			$ 187,500	0
Chief Executive Officer [Member] | Note Payable #19 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																							$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																							5%
Notes Payable																																			187,500	0
Chief Executive Officer [Member] | Note Payable #20 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																						$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																						5%
Notes Payable																																			187,500	0
Chief Executive Officer [Member] | Note Payable #21 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Face Amount																																			$ 187,500
Debt Instrument, Interest Rate, Stated Percentage																																			5%
Notes Payable																																			$ 187,500	0
Chief Scientific Officer [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Interest Payable																																			$ 770,585	$ 612,323
Chief Scientific Officer [Member] | Note Payable #5 [Member] | Notes Payable, Other Payables [Member]
RELATED PARTY TRANSACTIONS (Details) [Line Items]
Debt Instrument, Maturity Date														Nov. 07, 2019

RELATED PARTY TRANSACTIONS (D_2

RELATED PARTY TRANSACTIONS (Details) - Schedule of Related Party Transactions - USD ($)	Dec. 31, 2022	Dec. 31, 2021	Jun. 01, 2020
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 3,894,200	$ 3,144,200	$ 1,397,762
Northstar Claims [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	262,000	262,000
Chief Executive Officer [Member] | Note Payable #5 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	161,786	161,786
Chief Executive Officer [Member] | Note Payable #6 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Chief Executive Officer [Member] | Note Payable #7 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Chief Executive Officer [Member] | Note Payable #8 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	178,077	178,077
Chief Executive Officer [Member] | Note Payable #9 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	187,500	187,500
Chief Executive Officer [Member] | Note Payable #10 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	187,500	187,500
Chief Executive Officer [Member] | Note Payable #11 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	500,000	500,000
Chief Executive Officer [Member] | Note Payable #12 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	100,962	100,962
Chief Executive Officer [Member] | Note Payable #13 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	143,653	143,653
Chief Executive Officer [Member] | Note Payable #14 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	90,991	90,991
Chief Executive Officer [Member] | Note Payable #15 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	43,269	43,269
Chief Executive Officer [Member] | Note Payable #16 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	187,500	187,500
Chief Executive Officer [Member] | Note Payable #17 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	100,962	100,962
Chief Executive Officer [Member] | Note Payable #18 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	187,500	0
Chief Executive Officer [Member] | Note Payable #19 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	187,500	0
Chief Executive Officer [Member] | Note Payable #20 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	187,500	0
Chief Executive Officer [Member] | Note Payable #21 [Member] | Notes Payable, Other Payables [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Party	$ 187,500	$ 0

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($)				12 Months Ended
	Feb. 10, 2021	Jun. 15, 2019	Nov. 09, 2016	Dec. 31, 2021	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2022	Mar. 31, 2022	Feb. 26, 2022	Jun. 01, 2020	Feb. 05, 2020
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Royalty Agreement, Term			25 years
Revenue from Contract with Customer, Including Assessed Tax			$ 75,000
Percentage of Revenues to be Received as Royalty			5%
Deferred Revenue				$ 59,500			$ 56,500
General Insurance Expense					$ 11,000	$ 100,000
Settlement Liabilities, Current				26,600			25,810
Notes Payable				3,144,200			3,894,200			$ 1,397,762
Debt Instrument, Interest Rate, Stated Percentage		5.25%						0%			5%
Debt Instrument, Face Amount		$ 500,000							$ 25,000		$ 35,000
Debt Instrument, Periodic Payment		$ 5,000
Litigation Settlement, Expense				500,000
Proceeds from Sale of Long-Term Investments	$ 100,000
Unsecured Debt [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Notes Payable				413,239			403,622
Royalty Arrangement [Member]
COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Deferred Revenue				$ 59,500			$ 56,500

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details) - Lease, Cost - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lease, Cost [Abstract]
Operating lease expense	$ 6,541	$ 4,711
Total lease expense	$ 6,541	$ 4,711

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - USD ($)																	3 Months Ended	12 Months Ended
	Oct. 01, 2022	Apr. 05, 2022	Mar. 31, 2022	Mar. 11, 2022	Feb. 26, 2022	Oct. 01, 2021	Sep. 10, 2021	Apr. 01, 2021	Mar. 23, 2021	Feb. 10, 2021	Oct. 01, 2020	May 07, 2018	Aug. 07, 2017	Apr. 21, 2017	Sep. 16, 2016	Oct. 07, 2015	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Feb. 26, 2021	Dec. 31, 2020	Feb. 05, 2020	Jun. 15, 2019	Nov. 02, 2015	Aug. 04, 2014	Apr. 01, 2013
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other																		$ 384,174	$ 0
Convertible Debt Discount Increase Decrease																		241,589
Retained Earnings Increase Decrease																		142,585
Stock Issued During Period, Value, Other																		48,817	231,742
Gain (Loss) on Extinguishment of Debt	$ 450	$ 722				$ 274		$ (1,734)		$ 100,000	$ (984)						$ 447,494	(447,494)	0
Debt Conversion, Original Debt, Amount			$ 27,000	$ 25,000				9,145								$ 100,000		$ 25,000	$ 375,586
Stock Issued During Period, Shares, Issued for Services (in Shares)																		45,000,000	4,000,000
Stock Issued During Period, Value, Issued for Services																		$ 297,000	$ 128,000
Debt Conversion, Converted Instrument, Amount	$ 9,645	$ 9,866			$ 25,000	$ 8,921		$ 10,879
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	1,377,891	1,121,154	6,750,000	3,125,000	3,125,000	743,341		187,575	7,518,797		2,035,820					34,522			28,891,144
Common Stock Registered, Shares (in Shares)							250,000,000
Proceeds from Issuance of Common Stock																		$ 85,000	$ 275,000
Stock Issued During Period, Shares, New Issues (in Shares)																	53,400,000	13,958,334	27,500,000
Debt Instrument, Face Amount					$ 25,000																	$ 35,000	$ 500,000
Class of Warrant or Rights, Granted (in Shares)																	12,500,000	12,500,000	0
Class of Warrant or Rights, Weighted-Average Exercise Price of Warrants or Rights, Granted (in Dollars per share)																	$ 0.008	$ 0.008
Adjustments to Additional Paid in Capital, Warrant Issued																	$ 491,607
Extinguishment of Debt, Amount																	294,000
Debt Instrument, Unamortized Discount			$ 44,113														$ 44,113
Stock Issued During Period, Value, New Issues																		$ 85,000	$ 275,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value																		5,500	36,686		$ 296,636
Share-Based Payment Arrangement, Noncash Expense																		$ 384,380	$ 556,556
Debt Instrument, Maturity Date, Description																	extended for two years
Bioheart 2013 Omnibus Equity Compensation Plan [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)																								500,000,000,000,000	100,000,000	50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in Shares)												100,000,000	30,000,000	25,000,000	25,000,000
Maximum [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Proceeds from Issuance of Common Stock							$ 2,500,000
Interest [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)																		2,499,045	930,916
Stock Issued During Period, Value, Other																		$ 19,511	$ 19,800
Gain (Loss) on Extinguishment of Debt																		1,171	1,459
Debt Conversion, Original Debt, Amount																		$ 18,340	18,340
Debt Conversion, Converted Instrument, Amount																			586
Principal [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Debt Conversion, Converted Instrument, Amount																			$ 375,000
Convertible Debt [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Debt Instrument, Face Amount			$ 214,000														$ 214,000			$ 200,000
Debt Instrument, Convertible, Conversion Price (in Dollars per share)			$ 0.0266														$ 0.0266
Debt Instrument, Convertible, Conversion Price, Decrease (in Dollars per share)																	$ 0.008
Convertible Note February 26, 2022 [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, New Issues (in Shares)					6,750,000
Debt Instrument, Face Amount					$ 27,000
Debt Instrument, Unamortized Discount					18,563
Proceeds from Issuance of Debt					27,000
Stock Issued During Period, Value, New Issues					$ 18,563
Debt Instrument, Term					24 months
Accounts Payable [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Stock Issued During Period, Shares, Other (in Shares)																		6,145,193	6,642,197
Stock Issued During Period, Value, Other																		$ 48,817	$ 231,742
Gain (Loss) on Extinguishment of Debt																			151,742
Debt Conversion, Original Debt, Amount																		50,000
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Gain (Loss) on Extinguishment of Debt																		(1,183)
Share-Based Payment Arrangement, Option [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value																		$ 5,500
Share Price (in Dollars per share)																		$ 0.0048
Share-Based Payment Arrangement, Noncash Expense																		$ 134,974	$ 428,556
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount																		$ 22,315
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition																		5 months 19 days
Warrant [Member]
STOCKHOLDERS' DEFICIT (Details) [Line Items]
Share Price (in Dollars per share)																		$ 0.0048

STOCKHOLDERS' DEFICIT (Detail_2

STOCKHOLDERS' DEFICIT (Details) - Share-based Payment Arrangement, Option, Activity - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share Based Payment Arrangement Option Activity Abstract
Options Outstanding	110,643,884		111,119,914
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 0.0247		$ 0.0247
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 3 months 18 days	6 years 3 months 18 days	7 years 2 months 12 days
Options Outstanding, Intrinsic Value (in Dollars)	$ 5,500	$ 36,686	$ 296,636
Options exercisable	104,816,384
Options exercisable, Weighted-Average Exercise Price (in Dollars per share)	$ 0.0258
Options exercisable, Weighted-Average Remaining Contractual Term	5 years 2 months 12 days
Options exercisable, Intrinsic Value (in Dollars)	$ 5,500
Options Granted	0	0
Options Exercised	0	0
Forfeited/Expired	(2,500)	(476,030)
Forfeited/Expired, Weighted-Average Exercise Price (in Dollars per share)	$ 0.154	$ 0.0298
Options Outstanding	110,641,384	110,643,884
Options Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 0.0247	$ 0.0247

STOCKHOLDERS' DEFICIT (Detail_3

STOCKHOLDERS' DEFICIT (Details) - Share-based Payment Arrangement, Option, Exercise Price Range	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0247
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 3 months 18 days
Options Outstanding (in Shares) | shares	110,641,384
Options Exercisable (in Shares) | shares	104,816,384
Options Exercisable, Weighted-Average Exercise Price	$ 0.0258
Options $0.000 to $0.010 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0051
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years
Options Outstanding (in Shares) | shares	41,800,000
Options Exercisable (in Shares) | shares	35,975,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0051
Options $0.011 to $0.020 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0196
Options Outstanding, Weighted-Average Remaining Contractual Term	3 years 8 months 12 days
Options Outstanding (in Shares) | shares	16,250,000
Options Exercisable (in Shares) | shares	16,250,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0196
Options $0.021 to $0.030 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Weighted-Average Exercise Price	$ 0.0252
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 10 months 24 days
Options Outstanding (in Shares) | shares	9,510,000
Options Exercisable (in Shares) | shares	9,510,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0252
Options $0.0363 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.0363
Options Outstanding, Weighted-Average Exercise Price	$ 0.0363
Options Outstanding, Weighted-Average Remaining Contractual Term	4 years 7 months 6 days
Options Outstanding (in Shares) | shares	22,635,000
Options Exercisable (in Shares) | shares	22,635,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0363
Options, $0.0536 Exercise Price [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.0536
Options Outstanding, Weighted-Average Exercise Price	$ 0.0536
Options Outstanding, Weighted-Average Remaining Contractual Term	5 years 4 months 24 days
Options Outstanding (in Shares) | shares	20,000,000
Options Exercisable (in Shares) | shares	20,000,000
Options Exercisable, Weighted-Average Exercise Price	$ 0.0536
Options $0.1540 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.154
Options Outstanding, Weighted-Average Exercise Price	$ 0.154
Options Outstanding, Weighted-Average Remaining Contractual Term	2 years 9 months 18 days
Options Outstanding (in Shares) | shares	446,384
Options Exercisable (in Shares) | shares	446,384
Options Exercisable, Weighted-Average Exercise Price	$ 0.154
Minimum [Member] | Options $0.000 to $0.010 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.004
Minimum [Member] | Options $0.011 to $0.020 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.011
Minimum [Member] | Options $0.021 to $0.030 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.021
Maximum [Member] | Options $0.000 to $0.010 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.01
Maximum [Member] | Options $0.011 to $0.020 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	0.02
Maximum [Member] | Options $0.021 to $0.030 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 0.03

STOCKHOLDERS' DEFICIT (Detail_4

STOCKHOLDERS' DEFICIT (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Stockholders Equity Note Warrants Or Rights Abstract
Warrants Outstanding	1,103,127	1,103,127		1,110,468
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)	$ 12.41	$ 12.41		$ 12.84
Warrants Outstanding, Weighted-Average Remaining Contractual Term		4 years 3 months 18 days	6 years 2 months 12 days	7 years 1 month 6 days
Warrants Outstanding, Intrinsic Value (in Dollars)		$ 0	$ 0
Warrants Exercisable		13,581,582
Warrants Exercisable, Weighted-Average Exercise Price (in Dollars per share)		$ 0.12
Warrants Exercisable, Weighted-Average Remaining Contractual Term		4 years 3 months 18 days
Warrants Exercisable, Intrinsic Value (in Dollars)		$ 0	$ 0
Warrants Issued	12,500,000	12,500,000	0
Warrants Issued, Weighted-Average Exercise Price (in Dollars per share)	$ 0.008	$ 0.008
Warrants Exercised			0
Warrants Expired		(20,000)	(7,341)
Warrants Expired, Weighted-Average Exercise Price (in Dollars per share)		$ 15.5	$ 77.88
Warrants Outstanding		13,583,127	1,103,127
Warrants Outstanding, Weighted-Average Exercise Price (in Dollars per share)		$ 0.99	$ 12.41

STOCKHOLDERS' DEFICIT (Detail_5

STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 0.99	$ 12.41		$ 12.84
Warrants Outstanding, Shares (in Shares)	13,583,127	1,103,127		1,110,468
Warrants Outstanding, Weighted- Average Exercise Price	$ 0.99
Warrants Exercisable, Weighted- Average Remaining Contractual Term	4 years 3 months 18 days	6 years 2 months 12 days	7 years 1 month 6 days
Warrants Exercisable, Shares (in Shares)	13,581,582
Warrants Exercisable, Weighted- Average Exercise Price	$ 0.12
Class of Warrants or Rights, Exercise Price Range, $0.008- $0.03 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares (in Shares)	13,500,000
Warrants Outstanding, Weighted- Average Exercise Price	$ 0.01
Warrants Exercisable, Weighted- Average Remaining Contractual Term	4 years 3 months 18 days
Warrants Exercisable, Shares (in Shares)	13,500,000
Warrants Exercisable, Weighted- Average Exercise Price	$ 0.01
Class of Warrants or Rights, Exercise Price Range, $0.008- $0.03 [Member] | Minimum [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	0.008
Class of Warrants or Rights, Exercise Price Range, $0.008- $0.03 [Member] | Maximum [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 0.03
Class of Warrants or Rights, Exercise Price Range, $10.00 - $20.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares (in Shares)	61,036
Warrants Outstanding, Weighted- Average Exercise Price	$ 15.22
Warrants Exercisable, Weighted- Average Remaining Contractual Term	8 months 12 days
Warrants Exercisable, Shares (in Shares)	61,036
Warrants Exercisable, Weighted- Average Exercise Price	$ 15.22
Class of Warrants or Rights, Exercise Price Range, $10.00 - $20.00 [Member] | Minimum [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	10
Class of Warrants or Rights, Exercise Price Range, $10.00 - $20.00 [Member] | Maximum [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 20
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Shares (in Shares)	19,543
Warrants Outstanding, Weighted- Average Exercise Price	$ 25.06
Warrants Exercisable, Weighted- Average Remaining Contractual Term	1 year 2 months 12 days
Warrants Exercisable, Shares (in Shares)	19,543
Warrants Exercisable, Weighted- Average Exercise Price	$ 25.06
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member] | Minimum [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	20.01
Class of Warrants or Rights, Exercise Price Range, $20.01-$30.00 [Member] | Maximum [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	30
Class of Warrants or Rights, Exercise Price Range $49.86 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 49.86
Warrants Outstanding, Shares (in Shares)	1,003
Warrants Outstanding, Weighted- Average Exercise Price	$ 49.86
Warrants Exercisable, Weighted- Average Remaining Contractual Term	1 year 2 months 12 days
Warrants Exercisable, Shares (in Shares)	1,003
Warrants Exercisable, Weighted- Average Exercise Price	$ 49.86
Class of Warrants or Rights, Exercise Price Range, Greater than $60.00 [Member]
STOCKHOLDERS' DEFICIT (Details) - Schedule of Warrants Outstanding and Exercisable by Exercise Price Range [Line Items]
Warrants Outstanding, Exercise Price	$ 7,690
Warrants Outstanding, Shares (in Shares)	1,545
Warrants Outstanding, Weighted- Average Exercise Price	$ 7,690
Warrants Exercisable, Weighted- Average Remaining Contractual Term	4 years
Warrants Exercisable, Weighted- Average Exercise Price	$ 7,690

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 87.4	$ 79.7
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration		$ 5.7
Operating Loss Carryforwards, Limitations on Use	Section 382 of the Internal Revenue Code of 1986 (the “Code”) imposes an annual limit on the ability of a corporation that undergoes a greater than 50% ownership change to use its net operating loss carry forwards to reduce its tax liability. If in the future the Company issues common stock or additional equity instruments convertible in common shares which result in an ownership change exceeding the 50% limitation threshold imposed by Section 382 of the Code, the Company’s net operating loss carryforwards may be significantly limited as to the amount of use in a particular year.	limited to 80% of taxable income in the year utilized

INCOME TAXES (Details) - Schedu

INCOME TAXES (Details) - Schedule of Components of Income Tax Expense (Benefit) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Current:
Federal	$ 0	$ 0
State	0	0
Deferred:
Federal	1,263,199	843,633
State	261,362	174,551
	1,524,561	1,018,184
Change in valuation allowance	(1,524,561)	(1,018,184)
Income tax provision (benefit)	$ 0	$ 0

INCOME TAXES (Details) - Sche_2

INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating losses	$ 20,187,838	$ 22,139,733
Share-based compensation	4,405,938	4,371,729
Deferred compensation	1,213,463	1,023,375
Pre-litigation settlement notes payable	157,661	155,710
Accrued interest on deferred compensation	260,012	0
Other	154,546	274,703
Total deferred tax assets	26,379,458	27,965,250
Deferred tax liabilities:
OID on convertible debt beneficial conversion feature	0	(61,231)
Total deferred tax liabilities	0	(61,231)
Valuation allowance	(26,379,458)	(27,904,019)
Total	$ 0	$ 0

INCOME TAXES (Details) - Sche_3

INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Effective Income Tax Rate Reconciliation Abstract
US federal statutory rate	$ (600,168)	$ (690,357)
State tax rate, net of federal benefit	(92,413)	(137,277)
Effect of debt discount on convertible debt	(61,231)	166,437
Loss on settlement of debt	93,974	0
Effect of non-deductible Share-based compensation	52,375	0
Other	7,175	26,880
Effect of expiration of net operating loss carryforwards	2,124,849	1,652,501
Change in valuation allowance	(1,524,561)	(1,018,184)
Income tax provision (benefit)	$ 0	$ 0

CONCENTRATIONS (Details) - Sche

CONCENTRATIONS (Details) - Schedules of Customer Concentration Risk - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer One [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	14%	0%
Customer Two [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	12%	0%
Customer Three [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	11%	0%
Customer Four [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	0%	20%
Customer Five [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	0%	17%
Six Customers [Member]
Concentration Risk [Line Items]
Customer Concentration Risk, Percentage	37%	37%

CONCENTRATIONS (Details) - Sc_2

CONCENTRATIONS (Details) - Schedules of Credit Concentration Risk - Accounts Receivable [Member] - Credit Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer One [Member]
Concentration Risk [Line Items]
Credit Concentration Risk, Percentage	95%	98%
Two Customers [Member]
Concentration Risk [Line Items]
Credit Concentration Risk, Percentage	95%	98%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Event [Member] - shares	1 Months Ended
	Apr. 30, 2023	Mar. 31, 2023	Jan. 31, 2023
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services		4,000,000	1,125,282
Stock Issued During Period, Shares, Other	1,979,412